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Abstract
Arsenic, a ubiquitous environmental contaminant, has been shown to cause a
number of health effects. At high concentrations the inorganic form is a well-known
toxin, but at lower concentrations the effects range from various cancers, to
cardiovascular disease and type 2 diabetes. At higher concentrations of arsenic (5001000µg/L) there have been epidemiological studies conducted demonstrating an
increased risk in the development of type 2 diabetes with this exposure. At lower levels
of arsenic exposure (<500 µg/L) the epidemiological results are inconclusive. Arsenic is
also an immunotoxicant, meaning that it will cause changes in the immune response. The
changes in the immune response will vary depending on a number of variables, including
amount of arsenic exposure, forms of exposure and route of exposure. We wanted to
determine if arsenic could modulate the immune system, and if this change could lead to
an increase in susceptibility to type 2 diabetes development. We chose to examine this in
C57BL/6 and db/+ mice – two non-susceptible strains. After 8 weeks (4 weeks old to 12
weeks old) of low dose inorganic arsenic exposure (50 µg/kg or 500 µg/kg) we evaluated
changes in body composition, glucose tolerance and immune response. We saw that there
were differences based on sex, genotype and treatment group present after the 8-week
treatment period in body composition, while there were minimal changes in glucose
tolerance. Finally, the immune response showed great variability depending on sex,
genotype and treatment group. This project has demonstrated that while we are trying to
compare differences in in vivo and epidemiological studies to find a link between arsenic
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and type 2 diabetes, there may be deeper levels of complications based on individual
variability to arsenic exposure.
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Chapter 1 - Introduction
1.1 Arsenic
Arsenic is a ubiquitous element found in the earth’s crust that exists in organic
and inorganic forms. Unlike other elements, organic arsenic is currently believed to have
little impact on health, whereas inorganic arsenic is a known toxin. Typical arsenic
exposure is about 50 µg/day, with about 3.5 µg/day coming from inorganic sources
(ATSDR, 2013). Organic arsenic includes monomethylarsenous acid (MMA) and
dimethylarsinous acid (DMA), which are the main forms of arsenic excreted by humans.
Inorganic arsenic (iAs) is found in the pentavalent form iAs(V) or trivalent form iAs(III),
with the trivalent being the most toxic form humans are exposed to (Jomova et al., 2011).

1.2 Arsenic exposure: synthetic sources
We are exposed to arsenic through both natural and synthetic routes. Arsenic has
been used in medicine to treat a number of ailments including anemia, asthma, cholera
and syphilis giving it the nickname ‘Therapeutic Mule’ (Jolliffe, 1993; Przygoda,
Feldmann, & Cullen, 2001). To treat these ailments, several arsenic-containing solutions
have been used, including Donavan’s Solution (AsI3), de Valagin’s solution (AsCl3) and
Fowler’s Solution (1% potassium arsenite) until more recent and less toxic medical
advances were made (Przygoda et al., 2001; Scheindlin, 2005). Fowler’s Solution, which
is 1% potassium arsenite, was also used as an alternative to quinine for the treatment of
malaria (Scheindlin, 2005). More recently, arsenic has returned to use in medicine to treat
1

Acute Promyelocytic Leukemia (APL) in the form of Trisenox (Scheindlin, 2005). APL
has a very high relapse rate, and FDA-approved Trisenox is meant for these patients
(Scheindlin, 2005). After treatment with Trisenox, 70% of previously relapsed patients
were able to achieve complete remission (Scheindlin, 2005). In vitro, Chen et al.
demonstrated that arsenic trioxide induces apoptosis in the NB4 cell line, which gives a
potential mechanism for this treatment (G.-Q. Chen et al., 2003). However, future work is
still required to determine whether arsenic trioxide is a treatment option for other cancers.
Arsenic-containing compounds have also been used in industry as pesticides and
preservatives (Mandal & Suzuki, 2002). Chromated copper arsenate, or CCA, is the most
widely used wood preservative in the world and is used to create pressure treated wood
(ATSDR, 2013). While not allowed for residential use since 2003, CCA treated wood is
still used for nonresidential purposes, including utility poles (Hughes, Beck, Chen, Lewis,
& Thomas, 2011). However, with the ban in place it is currently unknown how CCAtreated wood contributes to total arsenic exposure (ATSDR, 2013).
In agriculture, arsenic compounds have been used in cotton fields and orchards
(Hughes et al., 2011). Lead arsenate was used in apple orchards until the 1960’s, when
health effects in orchard workers came into question (Hughes, 2002). While lead arsenate
is no longer used in agriculture, millions of acres of land are still contaminated with the
pesticide and can potentially impact the health of individuals living on or near this land
(Hughes et al., 2011) While inorganic arsenic can no longer be used in this capacity,
organic arsenic is still widely used on cotton (ATSDR, 2013). In industry, individuals
working in smelters are exposed to high levels of arsenic via inhalation. These
individuals are subjected to OSHA limits of up to 10 µg/m3 arsenic exposure, which is
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orders of magnitude higher than normal daily exposure (ATSDR, 2013). The greatest
health risk posed to these individuals is respiratory cancer.

1.3 Arsenic exposure: natural sources
Exposure to arsenic can occur naturally through contaminated soil, air and
water/food. Arsenic in the soil is typically in the inorganic form, with exposures in the
range of 0.1-40 mg/kg and average of 3-6 mg/kg (ATSDR, 2013; Mandal & Suzuki,
2002). This can differ greatly based on location, depending on the proximity to
agriculture, smelteries and arsenic rich soil deposits (Hughes et al., 2011).Typically,
arsenic in the soil does not cause a major problem unless the soil is being consumed.
However, arsenic in the soil becomes an issue when arsenic-rich deposits are the sites of
wells and water runoff into drinking water sources.
Humans are exposed to 1x10-3 to 2 µg/m3 inorganic arsenic from air sources, but
this can also vary based on location, weather, and industry presence (ATSDR, 2013). The
normal exposure in an unpolluted area is 0.04-0.09 µg/day (Mandal & Suzuki, 2002).
Arsenic exposure from air can also occur in certain work environments, like smelteries.
In these locations, OSHA limits have been established at 10 µg/m3, which is still orders
of magnitude higher than normal daily exposure (ATSDR, 2013). The most common
health concern for arsenic inhalation exposure is respiratory cancer. No other cancers
have been attributed to air exposure to arsenic which could be expected as inhalational
exposure also tends to begin later in life, unlike other exposures like through food and
water, which can be lifelong (Enterline, Day, & Marsh, 1995).
Food is the primary route of exposure to organic arsenic as well as high levels of
inorganic arsenic. The range of exposure from contaminated food is 20-140 ppb, which is
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a combination of both inorganic and organic species (ATSDR, 2013). Seafood
consumption is associated with increased levels or organic arsenic exposure, including
arsenobetaine and arsenocholine, but has not been shown to be associated with
carcinogenicity (Borak & Hosgood, 2007). Inorganic arsenic in food typically is highest
in chicken, rice, and apples, and there are few to no regulations in place to limit the
concentrations people are exposed to (Navas-Acien & Nachman, 2013). Apples and apple
juice are susceptible to arsenic contamination because, while arsenic has been banned for
use as a pesticide, persistent remnants in orchard soils from previous use are rapidly
taken up by these fruit trees (D. Wilson, Hooper, & Shi, 2012). In a study surveying the
amount of arsenic and lead in common grocery store apple juice brands, the range of
arsenic was 3.5-24.8 µg/L, the upper range of which is above the acceptable range of
arsenic in public drinking water. Rice can accumulate arsenic if it is grown in areas with
high arsenic in the soil or if it is cooked in water with high arsenic contamination
According to the Consumer Report, levels of inorganic arsenic per serving in rice and
cereals can range from 1.3-9.6 ppb (Consumer, November, Reports, Agency, & York,
2012). This is especially dangerous as rice is frequently used in children’s cereal and
snacks where multiple servings are consumed daily. The health impacts from consuming
arsenic in food are the same as those from other exposure sources, including cancer,
cardiovascular disease (CVD) and possibly type 2 diabetes (Davis et al., 2012).
Arsenic in drinking water has been a part of major regulatory changes in the past
decades. In the United States, arsenic levels in public drinking water have been regulated
by the Environmental Protection Agency (EPA), with a reduction from 50 µg/L to 10
µg/L occurring in 2001 because of its carcinogenicity (ATSDR, 2013). However, the
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range of arsenic exposure in drinking water in the United States is vast, from 0-10 µg/L
in public drinking water to 800 µg/L in private wells. In other countries such as
Bangladesh and Taiwan, the concentration of arsenic in drinking water can be well over
1000 µg/L. Arsenic at the levels in Bangladesh and Taiwan has contributed to the
development of skin lesions (arsenicosis) and a number of cancers, including skin, lung,
kidney bladder and liver (ATSDR, 2013); however, in the United States, a study found no
clear association between drinking water levels of ~100 µg/L and bladder cancer
(Steinmaus, Yuan, Bates, & Smith, 2003).
Besides cancer, high levels of arsenic have been attributed to a number of chronic
diseases. Argos et al. demonstrated in a range of arsenic exposures (0.1-864 µg/L)
approximately 22% of deaths associated with chronic disease could be attributed to
arsenic exposure greater than 10 µg/L drinking water in Bangladesh (2010). This study
used repeated measurements of total arsenic in urine over time in individuals, and thus
were able to demonstrate that decreasing arsenic exposure for a short period of time did
not reduce individual risks for disease. Sohel et al. examined non-accidental mortality in
Bangladesh caused by arsenic exposure and the increase for non-accidental death was
noted even at the lowest levels of exposure (10-49 µg/L) (2009). There was also an
increase in death from arsenic associated cancer, CVD, and infection in this population.
Finally, a number of epidemiological studies have been conducted examining the
association between arsenic and type 2 diabetes. In areas such as Bangladesh and Taiwan,
where arsenic levels in drinking water are high, there have been a number of studies
demonstrating a positive correlation between arsenic exposure and type 2 diabetes risk
(Nabi, Rahman, & Islam, 2005; M. Rahman, Tondel, Ahmad, & Axelson, 1998; Tsai,
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Wang, & Ko, 1999; C.-H. Tseng, Chong, Heng, Tseng, & Tai, 2000; S. L. Wang et al.,
2003, 2007). At lower exposures, for example in the United States where public drinking
water is heavily regulated, the literature is mixed; several studies that have found a
correlation between arsenic exposure and type 2 diabetes (Kuo et al., 2015; Lewis,
Southwick, Ouellet-Hellstrom, Rench, & Calderon, 1999; Meliker, Wahl, Cameron, &
Nriagu, 2007; Navas-Acien, 2008), while several other studies have found a weak
correlation between arsenic and type 2 diabetes (Gribble et al., 2012; James et al., 2013;
N. H. Kim et al., 2013) or no correlation at all (Steinmaus, Yuan, Liaw, & Smith, 2009;
Zierold, Knobeloch, & Anderson, 2004). Unfortunately, because of the wide range of
variables between studies, no common results have been produced. These
epidemiological studies, along with in vivo and in vitro studies attempting to find a link
between arsenic and type 2 diabetes will be reviewed later in this section.

1.4 Arsenic metabolism
The first step of arsenic metabolism occurs in the blood. Absorbed iAs(V) is
rapidly reduced to iAs(III) at least partially in the blood, from where it is distributed to
tissues and taken up by cells (ATSDR, 2013). The primary source of arsenic methylation
occurs in the liver; however, a couple of different theories exist to fully explain the
methylation of inorganic to organic arsenic. Methylation can occur through the classical
pathway [As(V) As(III)

MMA(V) MMA(III) DMA(V) DMA(III)] which is

catalyzed solely by Arsenic (III) methyltransferase (As3MT) (Thomas et al., 2009).
Alternatively, iAs(III) is conjugated to glutathione (GSH), forming several
arsenic:glutathione intermediates, however the end results are the same (Kumagai &
Sumi, 2007). Reviewed by Hughes et al., a number of early experiments helped solidify
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the function and location of S-adenosylmethionine (SAM) and GSH in the methylation of
arsenic in the liver (Hughes et al., 2011). Healy et al. examined arsenite
methyltransferase activity in B6C3F1 mice exposed to 0, 25 or 2500 µg/L arsenic for
either 32 or 91 days in the liver, testis, kidney and lung (Healy, Casarez, Ayala-Fierro, &
Aposhian, 1998). They found that the methyltransferase activity varied based on tissue,
with the testes having the highest level of activity, followed by kidney, liver, and lung,
respectively, independent of time or concentration of arsenic exposure.
The final step of arsenic metabolism is either storage in body tissues or excretion.
Small quantities of arsenic are stored in body tissues along with keratin-rich tissues
including hair and nails (Weir, 2002). The majority of arsenic is excreted in urine within
3 days, however a small percentage is excreted in breast milk (M Vahter, 2008) and/or
feces (Mandal & Suzuki, 2002). General proportions of urinary arsenic metabolites are
40-75% DMA, 20-25% iAs and 15-25% MMA as demonstrated in Figure 1.1, however a
number of variables will alter these amounts including exposure time, dose, route of
exposure, and arsenic species; sex and age of the individual (ATSDR 2013). Calderon et
al. examined changes in arsenic metabolism over a five-day period in a cohort consisting
primarily of members of the Church of Jesus Christ of Latter-Day Saints (1999). Day-today variation in arsenic excretion was low and no sex differences were reported, but they
did find differences in arsenic excretion based on age. This can be compared to the study
by Concha et al. that examined blood and urine arsenic levels in children and women in
three villages in northern Argentina (1998). Blood arsenic levels were 10x higher in both
women and children living in exposed villages (~200 µg/L in water) compared to
unexposed villages (1 µg/L). Urine arsenic levels were 30x higher in both women and
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children in the exposed area. Differences were noted in one of the villages where children
had a higher percentage of iAs and women had a much higher percentage of DMA, but
MMA was similar. These differences between adults and children could be due to
methylation deficiency, which will lead to age differences in arsenic metabolism
While the majority of studies have focused on MMA(V), Aposhian et al (2000)
found a dose-response relationship for arsenic in drinking water and urinary MMA(III).
MMA(III) is more toxic than inorganic arsenite, demonstrating that the methylation step
may not be a detoxification process of iAs. MMA(V) reductase is a rate-limiting enzyme
of the inorganic arsenite biotransformation pathway. When MMA(V) reaches critical
levels in the cell, it will be converted to MMA(III), so higher levels of exposure will have
higher levels of MMA(III) (Aposhian et al., 2000). This leaves a new variable for
epidemiological studies to consider in the analysis of urinary arsenic metabolites.

1.5 Mechanisms of arsenic
There are a number of proposed mechanisms for arsenic toxicity, including
enzyme inhibition, generation of reactive oxygen species (ROS) and epigenetic
mechanisms (X. Wu et al., 2016). While pentavalent arsenic is thought to be less toxic,
possible mechanisms include replacing phosphate in essential biochemical reactions (X.
Wu et al., 2016). It can replace glucose-6-phosphate and 6-phosphogluconate in vitro,
replace phosphate in the sodium pump, diminish formation of adenosine triphosphate
(ATP) by replacing phosphate and deplete ATP in cellular systems (ATSDR, 2013).
Arsenic (III) has the ability to inhibit multiple important enzymes by binding to the
sulfhydryl group (X. Wu et al., 2016). This alone has many downstream implications, as
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enzymes affected include but are not limited to kinases, phosphatases and caspases
(Miller, Schipper, Lee, Singer, & Waxman, 2002).
Arsenic (III) exposure also causes production of different forms of oxygen species
including H2O2 and OH radicals (X. Wu et al., 2016). The production of these reactive
oxygen species can cause inhibition of a number of cellular processes including DNA
repair, signal transduction and genotoxicity (X. Wu et al., 2016). The disruption of these
cellular processes is thought to be one of the main mechanisms behind the carcinogenesis
of arsenic exposure (X. Wu et al., 2016). Arsenic (III) can also cause DNA damage
because of its ability to replace phosphate, causing errors in DNA repair (Mandal &
Suzuki, 2002).

1.6 Type 2 Diabetes
Diabetes is a worldwide problem affecting 415 million people as of 2015, with the
number expected to increase to 642 million by the year 2040 (Federation, 2015). Type 1
diabetes is characterized by a deficiency of the body to produce insulin, caused by an
autoimmune disorder that causes pancreatic beta cell destruction (Federation, 2015;
World Health Organization, 2016). Onset of the disease appears typically in childhood
and is managed by lifelong insulin administration (Federation, 2015). Type 2 diabetes is
the most common form, and is characterized by insulin resistance leading to high blood
glucose (Federation, 2015). Perhaps the most challenging aspect of type 2 diabetes is that
the disease can go undiagnosed for many years, with approximately 193 million people
being affected and unaware (Federation, 2015). A number of different factors have been
attributed to the development of type 2 diabetes, many of them being lifestyle
management including poor nutrition, obesity, along with genetics and aging (Federation,
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2015; World Health Organization, 2016). However, we are now noticing a greater
increase in the number of type 2 diabetes cases than can’t be attributed to these factors
alone, making room for the possibility of environmental effects (Jeon, Ha, & Kim, 2015).
A number of studies have examined the effects of environmental contaminants on the
progression of type 2 diabetes, including effects of persistent organic pollutants,
bisphenol A and metals (Jeon et al., 2015). There is growing evidence that areas exposed
to high levels of arsenic also show increased incidence of type 2 diabetes, which will be
reviewed in the next section.

1.7 Review of Arsenic and Type 2 Diabetes Epidemiological Studies
A number of epidemiological studies have examined the possible link between
iAs exposure and type 2 diabetes, specifically iAs contamination of drinking water. In
some areas of Bangladesh and Taiwan, people are exposed to greater than 1000 µg/L, and
these areas not only have a high correlation between arsenic exposure and black foot
disease but also type 2 diabetes (Abernathy et al., 1999; Kuo, Moon, Thayer, & NavasAcien, 2013; Navas-Acien et al., 2006; W. Wang, Xie, Lin, & Zhang, 2014). As the
levels of arsenic drop to low or moderate exposure, the correlation is not as clear, as is
evident in Table 1.1. This can be because there is no clear mechanism discovered yet
between arsenic exposure and type 2 diabetes, but also a number of studies have very
different variables and exposure levels which makes drawing conclusions across the
board impossible. In my review of the epidemiological studies available from 1998-2016,
represented in Table 1.1, I excluded any studies that did not include original data, were
not related to arsenic exposure in drinking water, and lacked outcomes related to diabetes
or glucose metabolism.
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The range of exposure between all of the epidemiological studies is vast,
including regulated drinking water (0-10 µg/L) in the United States to the tube well
exposure in Bangladesh and Taiwan as high as 1400µg/L. Some studies failed to report
arsenic exposure, only reporting total urinary arsenic concentration as an indicator of
exposure (N. H. Kim et al., 2013; Y. Kim & Lee, 2011a; Navas-Acien, 2008; RuizNavarro, Navarro-Alarcon, Lopez Gonzalez-de la Serrana, Perez-Valero, & LopezMartinez, 1998; Steinmaus et al., 2009; S. L. Wang et al., 2007). While informative,
these studies lack the appropriate information to determine how their outcomes were
directly related to levels of arsenic exposure.
Urinary arsenic was the primary biomarker used for arsenic exposure in the
epidemiological studies. Compared to blood arsenic, which has a half-life of 1-4 hours,
urinary arsenic has a half-life of 4 days (NRC, 2001). Other possible biomarkers of
arsenic exposure include hair and nails as arsenic has a high affinity for keratin, and can
represent months to a year of exposure, respectively (NRC, 2001). It is difficult to
speciate arsenic from hair and nails and arsenic contamination may lie on the surface of
these biomarkers and must be removed before analysis is performed to avoid falsely
elevated detections (ATSDR, 2013; Mandal, Ogra, & Suzuki, 2003; Maull et al., 2012).
Mandal et al. did show that through the use of inductively coupled plasma mass
spectrometry (ICP-MS) it is possible to determine arsenic metabolites in these tissues,
including iAs(III), iAs(V), DMA(III) and DMA(V). However, urinary arsenic has been
the preferred marker for the majority of studies.
To give an accurate representation of total urinary arsenic, dilution of urine is
typically accounted for through the concentration of creatinine in urine. This can be
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calculated two ways – either by measuring µg urinary arsenic per gram of urinary
creatinine or by µg of urinary arsenic per liter of urine and measuring urinary creatinine
as a separate variable (Maull et al., 2012). The second method is the preferred method
because of the wide variety of individual variation in creatinine levels, however many
studies use both of these methods (Maull et al., 2012). Another issue in the use of
creatinine to determine urine dilution is that in diabetics, creatinine tends to be lower
because of increased glomerular filtration and increased water intake that leads to
increased urine dilution (Maull et al., 2012).
Studies also differ in the method used to diagnose diabetes. The options used
include self-report through the use of diabetic medication, physician diagnosis, fasting
blood glucose greater than 126 mg/dL or death certificate. Most studies use fasting blood
glucose of >127 mg/dL, but fasting times varied from 8-16 hours, with some studies
requiring dietary restrictions leading up to the exam (i.e. no seafood, as seafood is the
main source of organic arsenic exposure).
A number of studies also differ in the variables considered when determining total
urinary arsenic and diabetes. These variables include age, sex, ethnicity, body mass
index, education, smoking, alcohol consumption and seafood consumption. These
differences in population are very clear when comparing Meliker et al. and Lewis et al
(2007). These studies appear to be relatively similar, both populations living in the
United States, relying on death certificates to determine whether arsenic played a role in
increased type 2 diabetes mortality, and both populations were exposed to below an
average of 200 µg/L arsenic. However, the cohorts in each of these studies were very
different, with over 2000 individuals included in the Lewis study who were all Mormon
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whereas in the Meliker study, the cohort was significantly larger with over 80,000
individuals living in a more urban setting. These differences alone could contribute to the
differences in results; Lewis reported few incidences of type 2 diabetes-related deaths and
Meliker reported higher mortality rates associated with type 2 diabetes.
Two studies from the United States that used similar populations to evaluate
different end points were Gribble et al. and Kuo et al. (2012, 2015). Each of these studies
was based on populations from tribal areas of Arizona, Oklahoma, North and South
Dakota as a part of the Strong Heart Study. These locations have similar populations that
have low migration to other areas, which would keep the record of arsenic exposure
consistent. They also all fall below 61 µg/L for the range of arsenic exposure. Both
studies evaluated total urinary arsenic in relation to type 2 diabetes risk. Gribble found
that there was no association between urinary arsenic and diabetes risk in patients without
diabetes or with controlled diabetes. However, there was an association present in those
who participated in the study with uncontrolled diabetes, which was defined as
Hemoglobin A1c (Hb1Ac) ≥ 8%. Evaluating another endpoint, Kuo et al. determined that
there was a difference in type 2 diabetes risk depending on the breakdown of arsenic
metabolites in the urine. A higher percentage of MMA was associated with a decreased
risk of type 2 diabetes.
Both Navas-Acien et al. and Steinmaus et al. used data from the 2003-2004
National Health and Nutrition Examination Survey (NHANES) study, so the populations
were exactly the same (2008, 2009). However, each study accounted for inorganic
arsenic in total urinary arsenic differently, which was heavily evaluated by Longnecker
(2009). Steinmaus found no significant association in the same group of participants

13

when urinary metabolites that could come from seafood are excluded. Navas-Acien found
a positive correlation between urinary arsenic and type 2 diabetes, and instead of simply
subtracting organic urinary metabolites also noted that while DMA primarily comes from
iAs exposure, seafood can also contribute to DMA levels.
The remaining studies from the United States had relatively low numbers of
participants and were mixed in their results. Both Kim et al and James et al found mild
associations for the risk of type 2 diabetes with low arsenic exposure (2013, 2013).
Zierold et al. however found no association (2004). Both Kim et al. and James et al.,
required medical examination for participants, meaning individuals were diagnosed
diabetic either by self-diagnosis with a medical follow up or by glucose tolerance test,
where Zierold was only with self-diagnosed, lacking medical follow-up. These
differences in methods could lead to inconsistencies in diabetes reports at the conclusion
of studies.
Another issue with study design is that a number of the studies take place within
the same area, meaning that population overlap can be a problem. For example, the
studies that originated from Taiwan (Tsai et al., 1999; C.-H. Tseng et al., 2000; S. L.
Wang et al., 2003, 2007) all came from populations in the same area, which may skew
the only positive correlations between arsenic and diabetes found in these studies. The
same could be said for the studies that came out of Bangladesh (Y. Chen et al., 2010;
Islam et al., 2012; Nabi et al., 2005; M. Rahman et al., 1998). However, Chen et al. found
no evidence that type 2 diabetes was associated with arsenice exposure in the Bangladesh
population (2010). This study had large participation (n=11,319) and a wide range of
arsenic exposures, but the number of diabetes cases present was approximately 2% of the
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group. It is impossible to account for all of these variables within each study, however
this is a clear example of how streamlined variables need to be accounted for in
epidemiological studies.

1.8 Review of Arsenic and Type 2 Diabetes in Vivo Studies
Attempting to link the effects of arsenic and type 2 diabetes in vivo has had many of
the same complications that are present in epidemiological studies. These include, but are
not limited to: animal model used, differences in arsenic species, duration of exposure,
route of exposure and sampling methods. A number of animal models have been used to
investigate the potential role of arsenic on type 2 diabetes development, including mice,
rats, hamsters and guinea pigs. However, each of these animals metabolize arsenic
slightly differently from each other as well as humans. When evaluating urinary
metabolite breakdown, mice are the most similar to humans and one of the better options
for arsenic studies, with hamsters following up as a second choice (Mitchell, Ayala-fie, &
Carter, 2000). Rats are not suitable models as these models sequester arsenic in red blood
cells, which is very different from human metabolism. As such, only experimental studies
evaluating arsenic exposure and diabetic endpoints in mice will be reviewed.
In Table 1.2, it is apparent that a wide range of arsenic concentrations have been used
in mice, from 50 µg/L to 5x104 µg/L, which is orders of magnitude higher than human
exposures. However, higher concentrations of arsenic can be justified in mouse studies
because mice are known to have an overall faster metabolisms compare to humans.
The most common strain of mice used was C57BL/6, which could be because these
mice, when fed a high fat diet, are excellent models for obesity and diabetes. Also used
were ICR mice, which is an outbred strain, B6C3F1 mice that are a hybrid between
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C57BL/6 females and C3H males, and Swiss albino mice which are frequently used in
toxicology studies. One study also used diabetic C57BKS/Lepdb (db/db) mice and the
heterozygote (db/+) as a control (Liu et al., 2014). While the study by Huang et al.
included a non-diabetic variable (estrogen), it was essential to include this in the analysis,
as it is the only study that used female mice (2015). This is because it has been
demonstrated that there are differences in metal toxicity between males and females in
not only arsenic, but other metals as well (Marie Vahter, Åkesson, Lidén, Ceccatelli, &
Berglund, 2007)
Each study had a difference range and duration of arsenic exposure, ranging from a
single acute exposure to 20 weeks of chronic exposure. The most common route of
exposure was drinking water, although Mitchell et al. used intraperitoneal injection
(2000). A major problem with using arsenic in drinking water is that iAs(III) can oxidize,
so water must to be changed frequently. Another problem with arsenic in drinking water
is that depending on the number of mice in a cage, there was no way to definitively
determine how much arsenic each individual mouse drank. Finally, in some studies the
mice with arsenic in the drinking water actually consumed less water than the controls (D
S Paul, Devesa, & Hernandez-Zavala, 2008; David S. Paul, Hernandez-Zavala, et al.,
2007; David S. Paul, Walton, Saunders, & Styblo, 2011) which caused a reduction in the
overall arsenic exposure. Paul et al. concluded that because of the reduced arsenic
consumption in their low fat diet (LFD) treated mice, concentrations well above
5x104µg/L would have to be used to produce enough arsenic accumulation in tissues to
produce a change in glucose tolerance toward a diabetic phenotype (2011).
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Methods to evaluate glucose tolerance also varied from study to study (Table 1.2)
with fasting times ranging from 5 to 14 hours. Glucose bolus was either 1 g/kg or 2 g/kg
body weight with either oral glucose tolerance test (OGTT) or intraperitoneal glucose
tolerance test (IPGTT) was used to determine glucose tolerance, and glucose
measurements were typically taken at 0, 15, 30, 60, 90, and 120-minutes post glucose
bolus. The different conditions behind the oral glucose tolerance test have been tested to
determine ideal conditions (Andrikopoulos, Blair, Deluca, Fam, & Proietto, 2008).
Fasting for long periods of time (i.e. overnight) resulted in high fat and chow fed mice
having no differences in basal glucose and insulin levels, but 6 hours of fasting resulted
in a clear difference in glucose tolerance comparing high fat and chow fed animals
(Andrikopoulos et al., 2008). When comparing IPGTT and OGTT, IPGTT has a 10-20%
rate of error if the needle punctures the intestines or stomach, as well as differences in
glucose profiles. Plasma glucose levels are lower in the OGTT and IPGTT plasma insulin
increases at a slower rate (Andrikopoulos et al., 2008). Finally, they also examined the
amount of glucose to give mice, and when comparing 0.5 g/kg, 1 g/kg and 2 g/kg
glucose, only the 2 g/kg dose made a clear difference between chow and high fat diet.
With all of these variables between in vivo studies, only Mitchell et al. failed to report
arsenic having an impact on glucose tolerance (2000). A number of studies did report
issues with water consumption in the arsenic treated groups (D S Paul et al., 2008; David
S. Paul, Hernandez-Zavala, et al., 2007; David S. Paul et al., 2011), which resulted in
lower overall exposures to arsenic. Finally, since the majority of studies use only male
mice (Huang et al. is one exception since they used female mice), this did not allow for
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an evaluation of whether there are sex-based differences in arsenic exposure, metabolism
and glucose tolerance.

1.9 Review of Arsenic and Type 2 Diabetes in Vitro Studies
A number of in vitro studies have been conducted to provide a possible
mechanism behind arsenic and type 2 diabetes in mouse adipocytes, focusing primarily
on insulin-stimulated glucose uptake (ISGU). One problem caused by arsenic that has
been evaluated by a number of studies is the inhibition of differentiation into adipocytes
(Trouba, Wauson, & Vorce, 2000; Z. X. Wang et al., 2005; Wauson, Langan, & Vorce,
2002). This can be caused by exposure to arsenic reducing adipocyte protein 2 (aP2),
peroxisome proliferator-activated receptor gamma (PPARγ) and CCAAT/enhancerbinding protein alpha (C/EBPα), which are all important adipocyte markers (Wauson et
al., 2002). Also in 3T3-L1 adipocytes, 3uM arsenic trioxide was shown to inhibit PPARγ
and retinoid x receptor alpha (RXRα), as well as inhibiting interactions between
serine/threonine kinase Akt (or protein kinase B -PKB) and PPARγ, halting
differentiation in a reversible manner (Z. X. Wang et al., 2005). Hou et al., 2013, also
showed a reduction in adipogenesis caused by inducing the endoplasmic reticulum (ER)
stress response and upregulated CCAAT/enhancer-binding protein homologous protein
10 (CHOP10), which will inhibit CCAAT/enhancer-binding protein beta (C/EBPβ) and
suppress adipogenesis.
Another problem caused by arsenic is the inability of glucose transporter type 4
(GLUT4) to translocate to the cell membrane, which does not allow for glucose uptake
by the cell (David S. Paul, Harmon, Devesa, Thomas, & Styblo, 2007; Walton et al.,
2004; Xue et al., 2011). A number of possible arsenic targets have been identified,
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including PKB/Akt, which can be reduced by arsenic exposure (Walton et al., 2004) and
downregulation of GLUT4 expression (Xue et al., 2011).
All of these problems can also be attributed to the induction of oxidative stress in
the adipocytes by arsenic. Salazard et al. demonstrated an increase in Heme oxygenase 1
in adipocytes treated with arsenic, which is involved in oxidative stress along with an
increase in hypoxia-inducible factor 1 alpha (HIF1α) expression (2004). NAD-dependent
deacetylase sirtuin-3 (Sirt3) expression and target proteins forkhead box P3a (FOXO3a),
manganese superoxide dismutase (MnSOD), and peroxisome proliferator-activated
receptor gamma, coactivator 1 alpha (PGC-1α) were also reduced in long term, low level
arsenic exposure (Divya et al., 2015). These studies support the idea that arsenic can
induce oxidative stress, which can possibly be a cause of insulin resistance.
While these studies are very promising at providing potential mechanisms
between arsenic and type 2 diabetes, unfortunately none of them have been supported in
vivo or in a human system.

1.10 Arsenic and Inflammation
Finally, we will examine the effects of arsenic on the immune system. Depending
on the concentration and species of arsenic, very different impacts occur on the immune
system. When taking this into consideration in the context of diabetes, a disorder that is
normally associated with higher body mass index (BMI), another layer of inflammation is
added. The baseline inflammatory profiles between lean and obese individuals are very
different, so it would be expected that exposure to arsenic would impact these scenarios
very differently (Ferrante, 2007). The effects of arsenic on inflammation in humans and
mice have been extensively reviewed by (Dangleben, Skibola, & Smith, 2013; Mandal &
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Suzuki, 2002; Tobergte & Curtis, 2013). According to these sources, arsenic can not only
affect gene expression, but cell population, apoptosis, and ROS production in a number
of different immunological cell types. Because of the role of macrophages in obesity and
the differences in macrophages present in lean vs. obese individuals, we wanted to
explore the effects of arsenic on these immune cells in greater detail.
In humans, the majority of the studies have examined the effects of arsenic on
circulating peripheral blood mononuclear cells (PBMCs), not directly on macrophages. In
these studies, a number of different results have been seen depending on the
concentration of arsenic in question. In Bangladesh, a study examining 16 individuals, 5
control and 11 with skin lesions, reported downregulation of important immunological
genes, such as tumor necrosis factor alpha (TNF-α), expressed by PBMCs in circulation
(Argos et al., 2006). Another study in Mexico with 10 individuals, 5 control and 5 having
urinary arsenic concentrations ranging from 117.23-435.12 mg/g creatinine,
demonstrated that arsenic exposure correlates to suppression of a number of
inflammatory genes (Salgado-Bustamante et al., 2010). Both of these studies are
contradicted by a third study from Taiwan, with 24 individuals exposed to a range of
different concentrations of arsenic up to 46.5 µg/L (M.-M. Wu, Chiou, Ho, Chen, & Lee,
2008). This study documented an increase in gene expression in interleukin 1-beta (IL1β), interleukin 6 (IL-6), chemokine ligand 2 (CCL2) and cluster of differentiation 14
(CD14), all of which would indicate an increase in a pro-inflammatory immune
environment.
When comparing the effects of arsenic on macrophages in mice and humans the
results are very similar. Studies reported reduced macrophage adhesiveness, reduced
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cytokine response, and reduced nitric oxide production (Banerjee et al., 2009;
Bourdonnay et al., 2009; Sengupta & Bishayi, 2002; Srivastava et al., 2013). However, in
one study with PBMC-derived macrophages exposed to arsenic, as little as 1 µM As2O3
caused an exacerbated response to LPS as measured by TNF-α and interleukin 8 (IL-8)
mRNA production (Lemarie, Morzadec, Bourdonnay, Fardel, & Vernhet, 2006). Studies
in mice were performed either in peritoneal macrophages that were subsequently exposed
to arsenic, mice exposed to arsenic peritoneally then isolating macrophages from spleen,
or from strict cell culture using RAW264.7 cells (Sakurai et al., 2004; Sengupta &
Bishayi, 2002; Srivastava et al., 2013). In studies using sub-toxic levels of arsenic,
diminished macrophages functions as well as decreases in cytokines were present
including TNF-α, IL-1β, IL-6, transforming growth factor beta (TGF-β) and IL-10
(Sengupta & Bishayi, 2002; Srivastava et al., 2013). In another study, cytotoxic doses of
arsenic were used and an increase in TNF-α was reported (Sakurai, Kaise, & Matsubara,
1998).
Overall, a number of the studies investigating the effect of arsenic on
macrophages demonstrate the ability of the toxicant to reduce macrophage function,
diminish cytokine production and reduce nitric oxide production. The greatest differences
in study design occur in the concentration of arsenic used (cytotoxic vs non-cytoxic) or in
the method of arsenic exposure (PBMCs exposed to arsenic in vitro or PBMCs exposed
to arsenic in vivo then analyzed). As demonstrated in the epidemiological and in vivo
studies examining effects on arsenic, any small change between conditions can produce
very different results.
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1.11 Our Study in Arsenic and Type 2 Diabetes
In our study, we chose to use C57BL/6 mice along with the diabetic
C57BKS/Lepdb db/db and db/+ mice, however because of breeding issues we were left
with a large number of db/+ mice. These are considered the control in a number of
diabetes studies, so we wanted to see how these mice would compare to the background
C57BL/6 mice. We also chose to use both males and females in this study to determine
whether sex differences impacted the effects of arsenic exposure.
We chose to use AsCl3 for safety reasons, as it was the only option in solution that
was available. When added to water, it dissociates into iAs(III) and HCL at negligible
amounts. We used 0, 50 or 500 µg/kg concentrations and chose to deliver this by oral
gavage instead of in drinking water because we could guarantee each individual mouse
would receive the desired amount of arsenic. These concentrations also represent low
level exposure, as 50 µg/kg in a 20g mouse is a final exposure of 1 µg every other day –
which according to Table 1.3 is lower than most in Vivo studies have examined. The
second concentration, 500 µg/kg, is a final exposure of 10 µg every other day in a 20g
mouse, which while high is still not out of the range of previously studied concentrations
of arsenic in mice (Table 1. 3). Finally, for the in vitro study, we chose to use Raw 264.7
macrophages to determine the effect of arsenic on inflammation. Macrophages are an
important component of obesity and a number of studies have examined the effects of
PBMCs, but have not looked at the effect directly on macrophages.
Our goal for this study was to evaluate in a diabetic model the effects of low dose
arsenic exposure on the progression of type 2 diabetes development. We could claim that
we were measuring progression of the disease by the time point analysis of the dual
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energy X-ray absorptiometry (DEXA) scan and OGTT, which would have told us if
glucose tolerance was worsening over the period of arsenic treatment or if obesity was
increasing. We wanted to start the mice at a young enough age that obesity and glucose
dysregulation had not yet begun to be apparent. Our hypothesis based on the background
information provided was that arsenic exposure would increase inflammation, leading to
a diabetic phenotype in non-susceptible individuals.
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Table 1.1 Summary of Studies Examining Arsenic Exposure in Humans.
Reference

Location, number of
participants

Range of Exposure

Endpoint

Conclusion

Bangladesh
n = 11,319
Mexico
n = 400
cases = 200

Range = 0.1-864 µg/L

Total urinary arsenic and
HB1AC levels
Total urinary arsenic

No association between arsenic
exposure and T2D
No association at low levels of
urinary arsenic
High levels (>104 µg/g) have
2.65x higher probability of T2D
development

(Del Razo et al., 2011)
Cross-section

Mexico
n = 258

Mean = 42.9 µg/L
Range = 3.1-215.2
µg/L

Urinary arsenic
metabolites, fasting
blood glucose and 2hour blood glucose

(Feseke, Ayotte, Bouchard, &
Levallois, 2015)
Cross-section

Canada
n = 3151

Municipal sources <10 µg/L
Private wells undisclosed
Range = 1-61 µg/L

Total urinary arsenic

Found significant association
with arsenic concentration in
drinking water and fasting
blood glucose and 2-hour blood
glucose
Higher urinary arsenic levels
present in those with T2D and
prediabetes

Mean = 159 µg/L
Range = 10-1401 µg/L

Risk of T2D
development

(Y. Chen et al., 2010)
Cross-section
(Coronado-Gonzalez, Maria
Del Razo, Garcia-Vargas,
Sanmiguel-Salazar, &
Escobedo-de la Pena, 2007)
Case-Control

Range 20-400 µg/L
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(Gribble et al., 2012)
Cross-section

(Islam et al., 2012)
Cross-section

US – Arizona, Oklahoma,
North and South Dakota
n total = 3925
Nondiabetic n = 1,986
Diabetic n = 1,939
Bangladesh
n = 1004

Total urinary arsenic
HBA1C

No association between urinary
arsenic and HBA1C or insulin
resistance in people w/o
diabetes
Association restricted to
patients with uncontrolled
diabetes
Increased risk for T2D
development in >50 µg/L,
greatest risk at >250 µg/L for
greater than 10 years

United States – San Luis
Valley
Nondiabetic n =488
Diabetic n = 60
Serbia
Unexposed n = 1,324,489
Exposed n = 195,190

Mean 39 µg/L
Range – undetectable 752 µg/L

T2D Risks

Mild association for T2D risk at
levels <100 µg/L

No exposure
vs
56.1 µg/L

Number of diabetic cases
present

Higher number of diabetes
cases in exposed region

(Y. Kim & Lee, 2011b)
Cross-section

Korea
n = 1677

No range given

Total urinary arsenic

Higher urinary arsenic levels
present in those with T2D

(N. H. Kim et al., 2013)
Case-control

United States
n = 300

No range given

Risk of T2D
development

Slight association between
arsenic exposure and T2D risk

United States – Arizona,
Oklahoma, North and South
Dakota
n total = 3925
Nondiabetic n = 1,986
Diabetic n = 1,939
United States – Utah
n females = 961
n males = 1,242

Range = 1-61 µg/L

Urinary arsenic
metabolites

Higher MMA% in urine
associated with decreased T2D
risk

<200 µg/L

Mortality analysis

Few incidence of death
attributed to T2D

China
n = 669
United States – Michigan
n females = 41,282
n males = 38,722
Bangladesh
n = 235

Range = 0-760 µg/L

Risk of T2D
development
Mortality analysis

No significant association
between arsenic and T2D risk
Higher mortality rates observed
for T2D

Mean = 11.3 vs 218
µg/L
Range = 3 - 875 µg/L

Risk of T2D
development

Diabetes prevalence in exposed
individuals 2.8x higher than
unexposed

United States
n = 788

No range given

Total urinary arsenic

Total urinary arsenic levels are
associated with increased T2D

Bangladesh
Unexposed n = 854
Keratosis n = 251

I - <500 µg/L
II – 500-1000 µg/L
III – 1000 µg/L <

Number of diabetic cases
present

Increase in T2D cases in
patients with keratosis

(James et al., 2013)
Cases-Control

(Jovanovic et al., 2013)
Cross-section

(Kuo et al., 2015)
Case-Control
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(Lewis et al., 1999)
Retrospective
(Li et al., 2013)
Cross-Section
(Meliker et al., 2007)
Retrospective
(Nabi et al., 2005)
Case-control
(Navas-Acien, 2008)
Case-Control
(M. Rahman et al., 1998)
Cross-section

Average 11.0 µg/L

(Ruiz-Navarro et al., 1998)
Case-control
(Steinmaus et al., 2009)
Cross-section
(Tsai et al., 1999)
Retrospective

Spain
n = 89

No range given

Risk of T2D
development

No correlation to urinary
arsenic and T2D incidence

United States
Nondiabetic n = 697
Diabetic n = 98

No range given

Total urinary arsenic

No association between T2D
and urinary arsenic

Taiwan
n = 19,536

Mean = 790 µg/L
Range = 250-1140
µg/L
Range = 700-930 µg/L

Mortality analysis

Found correlation between
arsenic exposure and T2D
related mortality
Correlation between long term
arsenic exposure and T2D
Blood glucose is lower and
urinary arsenic higher in
arsenic exposed individuals
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(C. H. Tseng et al., 2000)
Cohort
(J. P. Wang et al., 2009)
Cross-section

Taiwan
n = 446
China
n = 235

(S. L. Wang et al., 2003)
Cross-section
(S. L. Wang et al., 2007)
Cross-section
(Zierold et al., 2004)
Case-Control

Range = 16-272 µg/L

Risk of T2D
development
Risk of T2D

Taiwan
n = 27,543
Taiwan
n = 660

Range >350 µg/L

Risk of T2D

No range given

Risk of T2D

US – Wisconsin
n = 1885

<2µg/L
2-10 µg/L
10 µg/L<

Evaluate prevalence of
chronic illness in
population

MMA – monomethylarsonic acid T2D- type 2 diabetes

Increased levels of T2D in
arseniases areas
Found correlation between
arsenic in hair and increased
blood glucose
No significant association
found

Table 1.2 Summary of in Vivo Studies Examining Arsenic and Type 2 Diabetes
In Vivo Study Parameters
Exposure
Endpoint
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Reference

Strain

(Huang et al.,
2015)

ICR
7-13 week old
females

Arsenic trioxide
(0, 50, 500 µg/L)
in drinking water
+ ovariectomized
or sham

Glucose
tolerance
and
estrogen

(Liu et al.,
2014)

C57BKS/Lepdr
(db/db and db/+)
7-23 week old
males

Sodium Arsenite
(0, 3000 µg/L) in
drinking water

Glucose
tolerance

(Mitchell,
Ayala-Fierro,
et al., 2000)

B6C3F1
Male adult 1x
exposure I.P.

Blood
arsenic
Blood
glucose

(David S. Paul,
HernandezZavala, et al.,
2007)

C57BL/6
4-12 week old
males

Sodium Arsenite
(0, 100, 1000
µg/L)
Sodium Arsenate
(0, 100, 1000
µg/L)
iAsIII (0, 2.5x104,
5x104 µg/L) in
drinking water

Glucose
tolerance

Conclusion

Arsenic
increased blood
glucose in
sham mice, and
caused an even
greater increase
in
ovariectomized
mice
Decreased
glucose
tolerance in
db/db mice

Glucose Tolerance Test
Glucose Fasting Time Measurement
Test
& Glucose
Times (min)
Bolus
OGTT
Overnight
0, 15, 45, 75,
1g/kg
105

OGTT

12 hours
2g/kg

0, 15, 30, 60,
90, 120

Blood arsenic
not a sign of
toxicity
No changes in
blood glucose

Blood
Glucose

x

x

Decreased
glucose
tolerance in

IPGTT

5 hours
2g/kg

0, 15, 30, 60,
90, 120

50ppm
treatment group
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(D S Paul et
al., 2008)

C57BL/6
4-12 week old
males

(David S. Paul,
Walton,
Saunders, &
Styblo, 2011)

C57BL/6
4-24 week old
males

(S. Rahman,
Hossain, &
Rahmatullah,
2016)

Swiss Albino
Mice
Male adult 1x
exposure

(Rodríguez,
LimónPacheco, Del
Razo, &
Giordano,
2016)

C57BL/6
Adult male 1 or
2-month
exposure

iAsIII (0, 1x103,
1x104, 2.5x104,
5x104 µg/L) or
MAsIII(0, 100,
1x103, 2.5x103,
5x103 µg/L) in
drinking water
iAsIII (0, 2.5x104,
5x104 µg/L) in
drinking water
+ high or low fat
diet
Sodium Arsenite
(0, 100, 200, 400
µg/20g body
weight) orally
Sodium Arsenite
(0, 5x104µg/L) in
drinking water

Glucose
tolerance

iAsIII impaired
glucose
tolerance at
5x104 µg/L

IPGTT

5 hours
2g/kg

0, 15, 30, 60,
90, 120

Glucose
tolerance

Higher blood
glucose in HFD
at 5x104 µg/L
compared to
LFD
Blood glucose
elevated at all
levels of
arsenic
exposure

OGTT

Overnight
2g/kg

0, 15, 30, 60,
90, 120

OGTT

Overnight
2g/kg

120

1 month did not
alter serum
glucose levels
2 months
decreased
glucose
tolerance

IPGTT

12 hour
2g/kg

0, 30, 90, 150

Blood
glucose

Blood
glucose

OGTT- oral glucose tolerance test, IPGTT, intraperitoneal glucose tolerance test

Inorganic
Arsenic
iAs (20-25%)

MMA (1525%)

DMA (40-75%)

Figure 1.1. Urinary inorganic arsenic metabolites. Common metabolites found in
urine that can be attributed to inorganic arsenic exposure are inorganic arsenic (iAs) (III)
and (V), monomethylarsonous acid (MMA) (III) and (V) and dimethylarsonous acid
(DMA) (III) and (V). Percentages are estimates of the concentrtion typically found in
human urine samples.

29

Range of Arsenic Exposure by Country
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Figure 1.2. Summary of arsenic exposure by country. Arsenic exposure varies from country to country, and presented are the
ranges of exposures that have been examined in epidemiological studies.

Huang 2015
Liu 2015
Mitchell 2000
Paul
Rahman 2016
Rodriguez 2016
Human Exposure

31

0

1000

2000

3000

4000

5000

6000

7000

8000

9000

10000

Range of Exposure (μg/L)

Figure 1.3. Range of in Vivo exposure compared to human exposure. In Vivo studies have attempted to provide a
link between arsenic exposure and type 2 diabetes, however these animal exposures tend to be much higher than to
human exposures.

Chapter 2 – Arsenic and Type 2 Diabetes in C57BL/6 Mice
2.1 Introduction
Arsenic is an element found in the earth’s crust that can be found in organic and
inorganic forms, with the inorganic form being a known toxin. Typical total arsenic
exposure is about 50 µg/day from a variety of sources, with about 3.5 µg/day coming
from the inorganic form and the rest coming for non-toxic organic sources such as
seafood (ATSDR, 2013). The main sources of inorganic arsenic exposure are from food
and water.
In the United States, the amount of arsenic in public drinking water is very highly
regulated, having been reduced from 50 µg/L to 10 µg/L by the EPA in 2001 because it is
a known carcinogen (ATSDR, 2013). In other countries however, the levels of drinking
water are not regulated and individuals are exposed to up to ten times the amount of
arsenic as in the United States. These include Bangladesh and Taiwan, where the well
water can be on the order of 1000 µg/L, leading to increased risks for health issues
including hyper-pigmentation, cardiovascular disease and type 2 diabetes, which have
been heavily reviewed (Becker & Axelrad, 2014; Huang et al., 2011; Navas-Acien et al.,
2006; Thayer, Heindel, Bucher, & Gallo, 2012; W. Wang et al., 2014). Other at risk areas
include rural populations in the United States that rely on well water and do not regularly
check for contaminants, as these sources of drinking water are not regulated. The
concentration of arsenic in these wells can also reach critical levels of almost 800 µg/L
(James et al., 2013).
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Type 2 diabetes is a metabolic disease that results in high blood sugar and insulin
resistance (Mathers & Loncar, 2006). This disease is typically considered a lifestyle
disorder resulting from inactivity, poor diet and high body mass index (BMI), but more
recently aging and genetic components are recognized to play a role in disease
development (Federation, 2015). In 2015, 415 million people were affected by type 2
diabetes with the number expected to increase to 642 million by the year 2040
(Federation, 2015). This increase in population is much greater than can be attributed to
lifestyle, age and genetics alone, which has led to research examining environmental
contaminants in the development of the disease, including but not limited to cadmium,
mercury and arsenic (Y. W. Chen et al., 2009).
While at higher levels positive correlations between arsenic exposure and type 2
diabetes have been demonstrated in the epidemiological data, at mid and lower level
exposure (<500µg/L) the results are inconclusive. Because of inconsistent methodologies,
comparing and contrasting data between studies at these levels is nearly impossible. The
same trend can be observed in animal studies, where at higher exposures glucose
intolerance can be induced by arsenic either acutely or chronically (Kuo et al., 2013).
While mice metabolize arsenic more rapidly than humans, the majority of these studies
use doses well beyond what would be considered relevant exposures for human studies.
In our study, we proposed to examine the diabetic effects of arsenic exposure on a nonsusceptible mouse strain at a concentration of arsenic that is closer to low-level exposure
in humans. The goal will be to determine if the lower level of arsenic we are exposed to
in the United States, which is highly regulated, is still enough to be concerned about
diabetes susceptibility. We will evaluate body composition, glucose tolerance and
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adipokine expression to elucidate a possible mechanism behind arsenic exposure leading
to the development of diabetes. We hypothesized that arsenic exposure would increase
obesity and decrease glucose regulation allowing for progression toward a diabetic
phenotype.

2.2 Methods and Materials
2.2.1 Animals
Male and female B6.BKS(D)Leprdb/J heterozygote mice were bred and housed at
the University of South Carolina Animal Resource Facility. Offspring of the heterozygote
x heterozygote cross were genotyped by RT-PCR followed by a restriction digest for the
Leptin gene at weaning (3 weeks of age). The primer sequences were forward: 5’AGAACGGACACTCTTTGAAGTCTC-3’; and reverse: 5’CATTCAAACCATAGTTTAGGTTTGTGT-3’. PCR products were digested using RsaI
enzyme, which cleaved sequences into one 135 base pair band or 27, 108, and 135 base
pair bands representing wildtype or heterozygous genotypes, respectively. Once
genotyped, animals were randomly grouped into control, 1x inorganic arsenic (AsCl3 Alfa Aesar, 50 µg/kg body weight) or 10x inorganic arsenic (500 µg/kg body weight) and
were treated every other day beginning at 4 weeks of age (Figure 2.1). These doses,
relating to human exposure, are 0, 1 and 10 µg every other day, respectively in a 20-g
mouse. This spectrum is broad enough to include a level of exposure lower and consistent
with current literature (Huang et al., 2015; Liu et al., 2014; Mitchell, Ayala-Fierro, et al.,
2000; D S Paul et al., 2008; David S. Paul, Hernandez-Zavala, et al., 2007; David S. Paul
et al., 2011; S. Rahman et al., 2016; Rodríguez et al., 2016). Mice received 100 µl/20 g
body weight of the appropriate dilution of arsenic (or diluent water for controls) via oral
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gavage using a flexible gavage needle. Weights were recorded every other day, and every
4 weeks an oral glucose tolerance test (OGTT) and Dual Energy X-ray Absorptiometry
(DEXA) scan were performed. Animals were maintained on a 12:12 hour light cycle and
given food and water ad libitum. At 12 weeks, animals were euthanized for tissue
collection using isoflurane overdose followed by cervical dislocation. Principles of
laboratory animal care were followed and the Institutional Animal Care and Usage
Committee of the University of South Carolina approved all protocols.

2.2.2 Body composition
Along with monitoring weight every other day, body composition was assessed
every four weeks (weeks 4, 8 and 12 of age). Mice were lightly anesthetized with
isoflurane and measurements were taken to determine lean mass, fat mass and body fat
percentage for each mouse by dual-energy X-ray absorptiometry (DEXA) (Lunar
PIXImus, Madison, WI).

2.2.3 Glucose tolerance
An oral glucose tolerance test (OGTT) was performed every four weeks following
arsenic exposure starting at 4 weeks old (weeks 4, 8 and 12 of age). Mice were fasted for
4 hours during their sleep cycle before initiating the OGTT with a fasting blood glucose
level. Glucose was given orally (2 mg/kg body weight) and blood glucose measurements
were taken from tail vein prick at 15, 30, 60, 90 and 120 minutes using TRUE test strips
and glucometer. Area under the curve (AUC) for the glucose tolerance test was calculated
using the trapezoidal rule.
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2.2.4 Tissue collection
Following 8 weeks of control or arsenic treatment, mice were euthanized for
tissue collection. Reproductive fat pads were collected for histology, preserved for 24
hours in 4% paraformaldehyde and then transferred to 70% ethanol before histology, or
snap frozen on dry ice and stored at -80ºC for triglyceride, protein and RNA analysis.
Spleen, liver, kidney, quadricep muscle and heart were also snap frozen and stored at 80ºC for protein and RNA analysis.

2.2.5 Histology
Reproductive adipose tissue was sectioned and stained with hemotoxylin and
eosin (H&E) to evaluate adipocyte size and diameter. Slides were evaluated using
AxioVision LE 4.8 software and ImageJ plugin Adiposoft (ver. 1.13) to measure
circumference and diameter for at least 2 fields of view for each section of tissue.
Histological score was conducted by two blinded reviewers independently and averaged.

2.2.6 Real-time PCR
RNA was isolated from reproductive adipose tissue by Isolate RNA kit according
to the manufacturer’s protocol (Bioline). RNA was converted to cDNA using SensiFAST
cDNA synthesis kit according to manufacturer’s protocol (Bioline). Real-time PCR
(qPCR) was then performed on 100 ng of cDNA using SensiFAST SYBR (Bioline) and
10 µM of designed and validated primers according to manufacturer’s protocol. Custom
primers (Table 2.1) were designed for each target using Primer Blast Search (NCBI) and
purchased from Integrated DNA Technologies (IDT) for qPCR. Gene expression patterns
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for each gene were normalized to the expression of the housekeeping gene RPLP0 and
quantified using the ΔΔCT method.

2.2.7 Triglycerides
Triglycerides were measured using saponification as previously described by
Jouihan (2012) using reagents from Sigma. Briefly, tissues were weighed and then
digested overnight at 55°C in ethanolic KOH. Digested tissue was diluted with 50%
ethanol, and 200 µl added to 215 µl 1M MgCl2. Samples were put on ice for 10 minutes.
Glycerol Standard Solution (2.5 mg/ml) was used to create a standard curve, and Free
Glycerol Reagent was used to spectrophotometrically determine triglyceride levels at
540nm based on the 8-point standard curve generated in triplicate.

2.2.8 Statistics
All statistical analyses were carried out using R (version 3.3.1) or GraphPad
Prism 7 (San Diego, CA). The n for each treatment group were as follows: male wildtype control (n=5), male wild-type arsenic (n=4), male heterozygote control (n=11), male
heterozygote arsenic 1x (n=8), male heterozygote arsenic 10x (n=3), female wild-type
control (n=6), female wild-type arsenic (n=5), female heterozygote control (n=9), female
heterozygote arsenic 1x (n=6), female heterozygote arsenic 10x (n=3), unless otherwise
noted. Three mice were excluded from all analyses as they were outliers in more than 3
different categories analyzed. Data are expressed as mean ± SEM. Regression analysis
were performed to compare exposure, genotypic and sex differences. A p-value of <0.05
was considered statistically significant.
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2.3 Results
2.3.1 Weight change
To determine whether arsenic affects the development of type 2 diabetes which
has an obesity component to the disease, we examined how exposure alters body
composition. We weighed mice every other day during the dosing period, and found that
when compared to the wild-type control, the slope of the male heterozygote control and
1x treatment group were significantly steeper showing greater change in weight (Figure
2.2a). This means that not only were there genotypic differences in weight gain, but
treatment based differences as well. However, the increase in arsenic exposure in the
heterozygotes from 1x to 10x did not further affect the weight change (Figure 2.2b).
When comparing the same effects in the females, all slopes in the change in weight were
significantly different from the wild-type control (Figure 2.3). This means that all groups
gained weight faster than the control, demonstrating both genotypic and treatment based
effects on weight.

2.3.2 Body composition analysis
From 4-8 weeks in males, there are no differences in body composition caused by
exposure to arsenic (Figure 2.4a). After the full dosing period (4-12 weeks), there is a
significant difference in the control wild-type and heterozygous males (Figure 2.4b).
While not significant, it does appear that arsenic causes a slight increase in fat mass and
percentage in wild-type males exposed to arsenic over the entire 12-week period (Figure
2.4b). In the heterozygote dose-response, arsenic appears to actually reduce the fat mass
from 4-8 weeks (Figure 2.4c). This trend is no longer present after the full dosing period
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(4-12 weeks), but the lean mass appears to be reduced in the 10x arsenic exposure group
compared to the other two treatments and the percent fat increased (Figure 2.4d).
In females there are small genotypic differences present starting between 4-8
weeks (Figure 2.5a) demonstrated by the female heterozygous controls having slightly
greater change in lean, fat and total mass compared to the wild-type control. These
changes are exaggerated when evaluating differences from 4-12 weeks (Figure 2.5b), as
the change in lean, fat and total mass are significantly greater in the heterozygote controls
compared to wild-type controls. In the heterozygote dose response, from 4-8 weeks the
10x arsenic treatment has a significant effect on the change in lean and total mass (Figure
2.5c); however, these changes do not persist through the entire dosing period (Figure
2.5d).

2.3.3 Oral glucose tolerance test
We hypothesized that if arsenic increased the risk of developing type 2 diabetes,
then we would see a decrease in glucose tolerance. Overall, arsenic did not appear to
have a major impact on the OGTT in males (Figure 2.6) We chose to break down the
glucose tolerance test into 2 measurable components – fasting blood glucose and area
under the curve. Arsenic does not affect the fasting blood glucose in males when
comparing wild-type to heterozygote over the 8-week dosing period (Figure 2.7). It
appears that the male heterozygotes exposed to arsenic had a higher baseline fasting
blood glucose, which was resolved at the end of the 8 weeks and no difference was
observed (Figure 2.7a). While the baseline fasting blood glucose in our male
heterozygote 10x treatment group started out lower than the other initial blood glucose
measurements, this trend remained constant during the duration of exposure (Figure
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2.7b). These results demonstrate that even with differences in baseline glucose tolerance,
arsenic did not cause reduced glucose tolerance during the course of exposure.
We also measured change in glucose tolerance through analyzing the area under
the curve of the glucose tolerance test (Figure 2.7c and 2.7d). There was no significant
difference in any genotype based on treatment group, although the male heterozygotes
begin with a slightly higher AUC and end with this intact. These results do not support
our hypothesis that arsenic will decreased glucose tolerance.
In the female OGTT, there was a significant difference in the peak of the curve in
the 12-week measurement between wild-type control and heterozygote controls (Figure
2.8c). Another significant difference occurred in the heterozygote dose response at the
baseline glucose tolerance test (Figure 2.8d). The 10x treatment group was significantly
lower than the 1x treatment group at the 30-minute time point. However, this did not
continue and is no longer visible in the 8-week (Figure 2.8e) or 12-week (Figure 12.8f)
curves. These finding show that while at certain time points, arsenic may cause slight
changes in glucose tolerance, over the duration of chronic exposure this change does not
persist and lead to sustained reduced glucose tolerance.
Breaking down the OGTT, we did see a significant difference in the fasting blood
glucose at 12 weeks between the wild-type and heterozygote controls shown by an
increase from 100 mg/dl in the controls to 120 mg/dl in the heterozygotes (Figure 2.9a).
No changes in the fasting blood glucose in the heterozygote dose response were observed
thereby supporting the idea that glucose tolerance is not altered by arsenic exposure
(Figure 2.9b). While there appeared to be a slight difference in AUC measurements in the
female heterozygote 1x treatment group at 4 weeks, this did not continue through to 12
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weeks (Figure 2.9c). This change was also not exacerbated by increasing the exposure to
arsenic (Figure 2.9d), further demonstrating that arsenic does not have an effect on
glucose tolerance in the wild-type or heterozygote females.

2.3.4 Histology
We expected that because there were differences in weight change, then there
would also be changes in adipose tissue morphology. Figure 2.10 presents representative
histological images of each treatment group. We analyzed these images to quantitate
adipocyte size and diameter in both males (Figure 2.11) and females (Figure 2.12). In the
male heterozygotes exposed to arsenic, there was an increase in size and diameter of
adipocytes analyzed, but this only applied to the 1x arsenic concentration and the change
was not significant (Figure 2.11a and b). At 10x, the male heterozygotes had reduced size
and diameter compared to the control heterozygotes, although again, the difference was
not significant (Figure 2.11c and d). This differs from the females, where there were no
changes in adipocyte size present (Figure 2.12). Overall, while we have demonstrated
that there were changes in weight gain, fat mass and lean mass these results did not
translate into the expected changes in adipose tissue morphology.

2.3.5 Gene expression
To examine the effects of arsenic on inflammation, which can alter the
inflammatory state both locally in adipose tissue and systemically, we examined the
expression of pro- and anti-inflammatory adipokines in males (Figure 2.13) and females
(Figure 2.14).
In wild-type males, arsenic had no significant effect on adipokine expression of
TNF-α, leptin or adiponectin However, it appears to increase adiponectin and decrease
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TNF-α in the arsenic-treated group compared to controls. This differs from the
heterozygotes, where arsenic significantly increases leptin expression in the 1x treatment
group (Figure 2.13e), which is not exacerbated by increasing the arsenic exposure to 10x.
In fact, the 10x treatment in heterozygotes appears to reduce the expression of
adiponectin, leptin and TNF-α compared to the 1x treatment, showing that increasing
arsenic exposure may actually diminish total immune response.
In female wild-type mice exposed to arsenic, there was a significant increase in
leptin expression (Figure 2.14b). Also while not significant, TNF-α expression appears to
be increased, (Figure 2.14c). In the heterozygotes, arsenic had no significant effect on
adipokine expression, although the 10x increased leptin and TNF-α expression compared
to both control and 1x exposures (Figure 2.14e and f). These results demonstrated that
even if arsenic does not have a significant effect on the immune system, depending on
individual genetics the immune response will be different.

2.3.6 Triglycerides
Because of the effects of arsenic on weight, we wanted to determine whether this
also altered triglyceride levels in various tissues throughout the body. We chose to
examine tissues that have been demonstrated to accumulate arsenic or be affected by
arsenic exposure, including the heart, kidney, liver and muscle.
In the males, arsenic had no significant effect on triglyceride levels (Figure 2.15),
however the 1x treatment group appeared to raise triglyceride levels slightly in the liver
and muscle, the 10x treatment group was reduced to levels very similar to control. In the
females, arsenic had no significant effect on triglyceride levels (Figure 2.16), while it
appeared that in the heterozygote group, 1x arsenic treatment increases heart and kidney
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triglycerides, the 10x treatment reduces these levels back to comparable to control. There
are significant genotypic differences present in the females in both the liver and heart
triglycerides (Figure 2.16c and d). The heterozygote females have higher triglyceride
levels in both organs, which may be attributed to them having larger lean, fat and total
mass compared to the wild-type mice, but overall arsenic had no impact on organ
triglyceride levels.

2.4 Discussion
The current literature is undecided as to whether arsenic plays a role in the
development of type 2 diabetes, especially at lower doses. We, therefore, sought to
examine the effects of arsenic on body composition, glucose tolerance and cytokine
expression in non-susceptible mice to determine whether these may contribute to
increased risks for the development of type 2 diabetes. Our results demonstrated that
there were no indicators of diabetes developing in these animals, but other changes that
could lead to increased susceptibility were observed such as an increase in systemic and
localized inflammation, which we will evaluate further in later studies.
Male and female wild-type mice are representative of a non-susceptible
population; however, type 2 diabetes can be induced when fed a high fat diet. We
examined whether arsenic would change the body composition in these mice, leading to
increased fat mass, decreased glucose tolerance and increased inflammation – all of
which could lead to the progression of diabetes. However, we found at the level of
arsenic used in these studies was insufficient to induce changes in glucose tolerance, but
it was enough to induce changes in weight gain and changes in inflammation in adipose
tissue.
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Arsenic alone is not a known inducer of obesity. In animal studies, arsenic
exposure, especially at higher levels, caused reduced water and food intake leading to a
slower, but not significantly different, increase in weight (D S Paul et al., 2008; David S.
Paul, Hernandez-Zavala, et al., 2007). In our animal model, both males and females
demonstrated that weight gain was increased during the period of arsenic exposure. One
of the major differences when comparing our study to others is the route of arsenic
exposure. Our mice were exposed every other day by oral gavage, where drinking water
exposures were used for other studies. The prolonged exposure may cause a decrease in
appetite that would damped weight gain during exposure periods.
The differences in body composition between female wild-type and heterozygote
controls were very prominent compared to males. The heterozygote females had a greater
increase in lean, fat and total mass from baseline to 12 weeks old when compared to the
wild-type females The only significant change in body composition we have reported that
is directly related to arsenic exposure is between the female heterozygote control and the
10x treatment group, where at this higher concentration of arsenic, we saw a decrease in
lean and total mass from 4-8 weeks. This however was no longer present at the
conclusion of the study, demonstrating that the body may be able to correct for some
changes over time even when challenged with a toxicant such as arsenic at low levels.
When comparing these to the adipose tissue histology, there was no difference in
adipocyte size or diameter in the arsenic treatment of males or females. Typically, in an
obese individual, the adipose tissue morphology will change. Adipocytes become larger
as obesity increases but because there was no difference in weight, only an increase in fat
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mass, this may be the reason for no difference. Different results may have been obtained
if other fat pads (visceral, subcutaneous) were examined for comparison.
While we may have reported differences in weight change in our treatment
groups, there were no changes in fasting blood glucose over the 12-week period. We
evaluated glucose tolerance by an OGTT, which we examined by analyzing the fasting
blood glucose and area under the curve. Typically, in a diabetic individual the fasting
blood glucose and area under the curve measurement will be much higher than a nondiabetic. In previous studies examining the effects of arsenic on glucose tolerance using
mice, changes in blood glucose tolerance were reported, but the concentration and
original form and route of arsenic exposure varied greatly (Huang et al., 2015; Liu et al.,
2014; D S Paul et al., 2008; David S. Paul, Harmon, et al., 2007; David S. Paul et al.,
2011; S. Rahman et al., 2016; Rodríguez et al., 2016). This may mean that the lower
levels of arsenic we used might not alter glucose tolerance over a short period of time.
Because of the changes in body weight, we wanted to determine whether there
was a concurrent affect in local inflammation in the adipose tissue. We examined three
adipokines that have different effects on the local and systemic immune system:
adiponectin (an anti-inflammatory cytokine), TNF-α and leptin, which are all proinflammatory cytokines. In the wild-type males, we observed a 2-fold increase in
adiponectin, which shows that while there were no significant changes in body
composition, arsenic induced a slight suppression in the local immune response. In the
male heterozygotes, which did have changes in body composition, leptin expression was
significantly upregulated 2-fold in the 1x treatment group or slightly increased in the 10x
treatment group.
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In females the inflammatory response was very different. In the wild-type
exposed to arsenic, there was a significant 2-fold increase in adipose tissue expression of
leptin accompanied by a slight increase in TNF-α, which can be attributed to this group
having a larger change in weight over the exposure time. The female heterozygotes had a
mixed immune response, with 1x arsenic treated mice having a 2-fold increase in
adiponectin and TNF-α and the 10x treatment group having a 2-fold increase in leptin
and TNF-α, although none of the changes were significant. Both of these treatment
groups had very similar weight changes, so the differences in response must be the result
of the concentrations of arsenic used. The increase in arsenic in the 10x group may have
been sufficient to overstimulate the pro-inflammatory response and reduce the expression
of adiponectin.
We chose to examine triglycerides because of the varying changes arsenic caused
in body composition. All of the organ triglyceride levels measured in this experiment
have been shown to be increased in diabetic cases (Christoffersen et al., 2003; Kelley &
Goodpaster, 2001; Shimomura, Bashmakov, & Horton, 1999; Sun, 2002). While we saw
minimal indicators of diabetes, the majority of the changes in these organ triglycerides
can be attributed to the changes in fat or body weight over the duration of treatment. So
by modifying body composition, arsenic also affected triglyceride content in different
organs in the body.
Overall, our study demonstrated that the effects caused by arsenic differ, not only
by concentration of exposure and sex but by genotype as well. None of the systems
affected by arsenic responded similarly within these different models. In the future,
adding in the db/db genotype will allow us to determine how arsenic affects an individual
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that will genotypically develop type 2 diabetes at an early age. It would also be beneficial
to compare this study to a diet-induced diabetes model using the same mice to determine
whether our parameters would change as obesity increases. Adding these two pieces of
the puzzle would allow us to not only compare the mechanisms by which arsenic affects
a non-susceptible individual to a diet-induced obese individual but also affects in a
genetically-induced obese individual.
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Table 2.1. Real-time PCR Primer List.
ID
Forward 5’-3’

Reverse 5’-3’

Adiponectin

CTACTGCAACATTCCGGGAC

TGCGAATATTGTGAAGCCCC

Leptin

GACATTTCACACACGCAGTC

GAGTCATGCCTTTGGATGGG

TNF-α

AGCACAGAAAGCATGATCCG

CTACAGGCTTGTCACTCGAA

RPLP0

CCTGAAGTGCTCGACATCAC

GCGCTTGTACCCATTGATGA

Abbreviations: Tumor necrosis factor alpha – TNF-α, Ribosomal protein lateral stalk
subunit P0 – RPLP0
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Figure 2.1 Experimental layout. Starting at the age of 4 weeks, mice will begin arsenic
exposure and weighing every other day (EOD). This will also be the baseline oral glucose
tolerance test (OGTT) and dual-energy X-ray absorptiometry (DEXA) scan. These tests
will be repeated at week 8 and week 12, when the study will conclude.
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Figure 2.2. Change in weight in male wild-type and heterozygotes after 8 weeks of arsenic exposure. Mean weight change for
each genotype (WT – wild-type, Het – heterozygote) over time. A) Compared to wild-type controls, the mean change in weight for het
male controls and iAs 1x was significantly greater. B) Increase in arsenic exposure did not alter average change in weight for control,
1x, and 10x hets. Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using linear
regression and is indicated as * (p<0.05).
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Figure 2.3. Change in weight in female wild-type and heterozygotes after 8 weeks of arsenic exposure. Mean weight change for
each genotype (WT – wild-type, Het – heterozygote) over time. A) Compared to wild-type controls, the mean change in weight for
iAs-treated WT and het females was significantly greater over the 8-week dosing period. B) Increase in arsenic exposure did not
increase the mean change in weight for control, 1x, and 10x hets. Data are represented as the mean of each treatment group ± SEM
Statistical significance was assessed using linear and is indicated as * (p<0.05).
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Figure 2.4. Mean change in body composition in males. Change in DEXA scan results from male WT and hets at 4-8 weeks (A and
B) and from 4-12 weeks (C and D) after arsenic exposure. Arsenic had no effect on body composition, however the lean mass in the
male het control from 4-12 weeks had a significantly greater increase compared to wild-type control. Data are represented as the mean
of each treatment group ± SEM. Statistical significance was assessed using linear regression followed by Tukey’s multiple comparison
test and is indicated as * (p<0.05).
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Figure 2.5. Mean change in body composition in females. Change in DEXA scan results from female WT and heterozygotes at 4-8
weeks (A and B) and from 4-12 weeks (C and D) after arsenic exposure. From 4-8 weeks, 10x arsenic significantly reduced the
change in lean and total mass in female hets compared to control, however this did not persist until 12 weeks. From 4-12 weeks,
arsenic had no effect on body composition, however the control female hets had a greater increase in lean, fat and total mass compared
to wild-type controls. Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using
linear regression followed by Tukey’s multiple comparison test and is indicated as * (p<0.05).
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Figure 2.6. Male oral glucose tolerance test (OGTT) curves. Change in glucose tolerance during oral glucose tolerance test in male
wild-type and heterozygotes at 4 (A, B), 8 (C, D) and 12 (E, F) weeks old after arsenic exposure. While significant differences were
present at the 15-minute time point in the male hets at the baseline OGTT measurement, no changes were persistent through the entire
dosing period. Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using ANOVA
followed by Tukey’s multiple comparison test and is indicated as * (p<0.05).
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Figure 2.7. Changes in male glucose tolerance. Change in fasting blood glucose (A and B) and area under the curve (C and D) in
male wild-type and heterozygous mice after 8 weeks of arsenic exposure. Neither arsenic nor genotype significantly affected FBG or
AUC measurements. Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using
linear regression followed by Tukey’s multiple comparison test and is indicated as * (p<0.05).
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Figure 2.8. Female oral glucose tolerance test (OGTT) curves. Change in glucose tolerance during oral glucose tolerance test in
female wild-type and heterozygous mice at 4 (A, B), 8 (C, D) and 12 (E, F) weeks old after arsenic exposure. While a significant
increase in blood glucose are present at the 30-minute time point in the female 1x hets at baseline, this difference is not exacerbated by
arsenic over the dosing period. Arsenic did significantly increase the peak at 15 minutes in the 12 week OGTT in female het control
compared to wild-type control. Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed
using ANOVA followed by Tukey’s multiple comparison test and is indicated as * (p<0.05).
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Figure 2.9. Changes in female glucose tolerance. Change in fasting blood glucose (A and B) and area under the curve (C and D) in
female wild-type and heterozygous mice after 8 weeks of arsenic exposure. While arsenic exposure did not significantly affect FBG or
AUC measurements, wild-type controls had a lower fasting blood glucose at 12 weeks compared to het controls. Data are represented
as the mean of each treatment group ± SEM. Statistical significance was assessed using linear regression followed by Tukey’s
multiple comparison test and is indicated as * (p<0.05).
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Figure 2.10. Reproductive adipose tissue histology. H&E sections from males (column 1) and females
(column 2). A) WT Control B) WT iAs C) Het Control D) Het iAs (1x) E) Het iAs (10x). Images are at 4x
magnification. Statistical significance was assessed using linear regression followed by Tukey’s multiple
comparison test and is indicated as * (p<0.05).
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Figure 2.11. Arsenic does not significantly alter male reproductive adipose tissue histology. Software analysis of reproductive fat
histological sections reveal that there are no significant differences in adipocyte diameter or area in wild-type or het males. Graphs
represent the male adipocyte area (A and B) and diameter (C and D) analyzed using Adiposoft software and data are represented as the
mean of each treatment group ± SEM. Statistical significance was assessed using linear regression followed by Tukey’s multiple
comparison test and is indicated as * (p<0.05).
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Figure 2.12. Arsenic does not significantly alter female reproductive adipose tissue histology. Software analysis of reproductive
fat histological sections reveal that there are no significant differences in adipocyte diameter or area in wild-type or het females.
Graphs represent the female adipocyte area (A and B) and diameter (C and D) analyzed using Adiposoft software and data are
represented as the mean of each treatment group ± SEM. Statistical significance was assessed using linear regression followed by
Tukey’s multiple comparison test and is indicated as * (p<0.05).
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Figure 2.13. Arsenic significantly increases leptin expression in male heterozygote reproductive adipose tissue. Graphs A, B and
C represent wild-type vs heterozygote gene expression and graphs D, E and F represent heterozygote dose response gene expression.
Arsenic exposure significantly increased leptin expression in reproductive adipose tissue compared to control, but this was not
exacerbated by 10x exposure. Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed
using linear regression followed by Tukey’s multiple comparison test and is indicated as * (p<0.05).
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Figure 2.14. Arsenic significantly increases leptin expression in female wild-type reproductive adipose tissue. Graphs A, B and
C represent wild-type vs heterozygote gene expression and graphs D, E and F represent heterozygote dose response gene expression.
Arsenic exposure increases expression of leptin in wild-type females exposed to arsenic compared to controls. Data are represented as
the mean of each treatment group ± SEM. Statistical significance was assessed using linear regression followed by Tukey’s multiple
comparison test and is indicated as * (p<0.05).
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Figure 2.15. No differences present in male organ triglycerides. Graphs A-D represent wild-type vs heterozygote triglycerides in
different organs and graphs E-H represent heterozygote dose response triglycerides in different organs. There are no significant
changes in triglyceride levels in the heart, kidney, liver or muscle caused by arsenic exposure or genotype differences. Data are
represented as the mean of each treatment group ± SEM. Statistical significance was assessed using linear regression followed by
Tukey’s multiple comparison test and is indicated as * (p<0.05).
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Figure 2.16. Female heterozygote controls have higher levels of liver and muscle triglycerides compared to wild-type controls.
Graphs A-D represent wild-type vs heterozygote triglycerides in different organs and graphs E-H represent heterozygote dose
response triglycerides in different organs. Arsenic exposure did not change triglyceride levels in the heart, kidney, liver or muscle.
However, female het controls had significantly higher levels of liver and muscle triglycerides compared to wild-type controls. Data are
represented as the mean of each treatment group ± SEM. Statistical significance was assessed using linear regression followed by
Tukey’s multiple comparison test and is indicated as * (p<0.05).

Chapter 3 – Arsenic and Inflammation
3.1 Introduction
Arsenic, a ubiquitous element, is a known toxin in its inorganic form. Humans are
exposed to about 50 µg/day, 3.5 µ/day coming from inorganic sources in food and water
(ATSDR, 2013). Because arsenic is a well-known carcinogen, in an attempt to reduce
levels of exposure the amount of arsenic in public drinking water is very highly
regulated, with a relatively recent reduction in action level from 50 µg/L to 10 µg/L by
the EPA in 2001 (ATSDR, 2013). Besides cancer, arsenic is known to affect a number of
different organ systems and has been linked to cardiovascular disease, type 2 diabetes and
immunological disorders (Mandal & Suzuki, 2002). It has been demonstrated that at
higher concentrations (>500 µg/L), arsenic may increase susceptibility to type 2 diabetes,
but at lower concentrations the results are inconclusive (Huang et al., 2011; Navas-Acien
et al., 2006). The effects of arsenic on inflammation in humans and mice have been
extensively reviewed by Dangleben et al., Mandal and Suzuki, and Tobergte and Curtis
(2013; 2002; 2013). According to these sources, arsenic can alter gene expression,
immune cell population, and ROS production that can lead to either a range of different
consequences from a suppressed immune system to a pro-inflammatory immune state,
however the results will vary based on the concentration of arsenic in question. While the
majority of studies have focused on higher levels of arsenic exposure and the effects on
the immune system, there is still a lot unknown about how low-level arsenic exposure can
affect the immune response.
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When considering the effects of arsenic on inflammation, the baseline
inflammatory profile is an important component to be considered. In lean individuals,
there is a balance in the inflammatory state. However, as BMI increases, the
inflammatory profile shifts towards a more pro-inflammatory state that is both local in
the adipose tissue and systemic (Mosser & Edwards, 2008). Thus, it is important to
determine whether arsenic affects metabolic diseases, such as type 2 diabetes, where
changes in inflammation may play a vital role in the progression of the disease. In our
study we propose to examine the effects of arsenic on the immune system in both sexes
of two lean mouse strains – C57BL/6 and db/+ at low (50 µg/kg) and high (500 µg/kg)
levels of arsenic. This will allow us to begin to determine whether there are sex
differences in the immune response induced by arsenic exposure and to examine the role
of genotype in these lean mice. We will evaluate inflammation by examining systemic
cytokine profiles and organ-specific gene expression. This will be compared to the
overall change in body composition in these mice to determine whether the inflammatory
profile changes as a result of arsenic exposure or due to changes in the mouse fat mass.
Based on current literature and the results at high levels of arsenic exposure, we
hypothesize that in these lean mice, arsenic will increase systemic and local
inflammation.

3.2 Methods
3.2.1 Animals
Male and female B6.BKS(D)Leprdb/J heterozygote mice were bred and housed at
the University of South Carolina Animal Resource Facility. Offspring of the heterozygote
x heterozygote cross were genotyped by RT-PCR followed by a restriction digest for the
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Leptin gene at weaning. The primer sequences were forward: 5’AGAACGGACACTCTTTGAAGTCTC-3’; and reverse: 5’CATTCAAACCATAGTTTAGGTTTGTGT-3’. PCR products were digested using RsaI
enzyme, which cleaved sequences into one 135 base pair band or 27, 108 and 135 base
pair bands representing wildtype or heterozygous genotypes, respectively. Once
genotypes, animals were grouped into control, 1x inorganic arsenic (AsCl3 - Alfa Aesar,
50µg/kg) or 10x inorganic arsenic (500µg/kg) and were gavaged every other day.
Weights were recorded every other day starting when the mice were 4 weeks old, and
every 4 weeks an oral glucose tolerance test (OGTT) and Dual Energy X-ray
Absorptiometry (DEXA) scan were performed. Animals were maintained on a 12:12 hour
light cycle and given food and water ad libitum. At 12 weeks, animals were sacrificed for
tissue collection using isoflurane overdose followed by cervical dislocation. Principles of
laboratory animal care were followed and the Institutional Animal Care and Usage
Committee of the University of South Carolina approved all experiments.

3.2.2 Tissue collection
Mice were euthanized at 12 weeks of age for tissue collection. Blood was
collected by cardiac puncture and serum separated for cytokine analysis. Reproductive
adipose tissue was collected for histology, preserved for 24 hours in 4%
paraformaldehyde and then transferred to 70% ethanol before histology, or snap frozen
on dry ice and stored at -80ºC for triglyceride, protein, and RNA analysis. Spleen, liver,
kidney, thigh muscle and heart were also snap frozen and stored at -80ºC for protein and
RNA analysis.
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3.2.3 Cytokine analysis
Spleen and serum cytokines were measured by multiplex bead-based assay (BioPlex, Bio-Rad) according to manufacturer’s protocol for the following cytokines:
interleukin (IL)-1β, IL-4, IL-6, IL-10, IL-13, interferon (IFN)-γ, granulocyte macrophage
colony-stimulating factor (GMCSF) and tumor necrosis factor (TNF)-α. Limits of
detection were as follows in the spleen (in pg/ml): IL-1β=28.11, IL-4=3.59, IL-6=1.01,
IL-10=11.03, IL-13=53.43, IFN-γ=14.09, GMCSF=9.37 and in the serum (in pg/ml): IL1β=60.52, IL-6=1.27 and TNF-α=53.82. Standard curves were generated in triplicate.
Cytokine measurements below the limit of detection were assigned a value of the limit of
detection/√2 for statistical analysis and plotting. TNF-α levels were measured in
homogenized spleen using ELISA kits (eBioScience) according to the manufacturer’s
instructions, with a limit of detection of 8 pg/mL.

3.2.4 Gene expression
RNA was isolated from reproductive adipose tissue according to the
manufacturer’s protocol (Bioline Isolate RNA kit). RNA was converted to cDNA using
SensiFAST cDNA synthesis kit according to manufacturer’s protocol (Bioline). Realtime PCR was then performed on 100ng of cDNA using SensiFAST SYBR (Bioline) and
10µM of designed and validated primers according to manufacturer’s protocol. Custom
primers (Table 3.1) were designed for each target using Primer Blast Search (NCBI) and
purchased from Integrated DNA Technologies (IDT) for qPCR. Gene expression patterns
for each gene were normalized to the expression of the housekeeping gene RPLP0 and
quantified using the ΔΔCT method.
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3.3 Statistics
All statistical analyses were carried out using Stata for linear regression and
Tukey’s post-test. The n for each treatment group were as follows: male wild-type control
(n=5), male wild-type arsenic (n=4), male heterozygote control (n=11), male
heterozygote arsenic 1x (n=8), male heterozygote arsenic 10x (n=3), female wild-type
control (n=6), female wild-type arsenic (n=5), female heterozygote control (n=9), female
heterozygote arsenic 1x (n=6), female heterozygote arsenic 10x (n=3), unless otherwise
noted. Three mice were excluded from all analyses as they were outliers in more than 3
different categories analyzed. Data are expressed as means ± SEM. Regression analysis
were performed to compare exposure, genotypic, and sex differences. A p-value of <0.05
was considered statistically significant.

3.4 Results
3.4.1 Effect of arsenic on fat mass
We predicted that arsenic exposure would cause changes in body composition that
would affect systemic inflammation. In order to determine whether the effects on the
immune system were caused by change in body fat or by arsenic, we first plotted the
change in body fat from baseline (4 weeks) to 12 weeks of age for both males and
females (Figure 3.1). While the male heterozygous animals appear to have a greater
change in body fat after 8 weeks of 1x arsenic exposure, the change was not significant.
The only difference found to be significant based on genotype was between female wildtype control and female heterozygotes, indicated by an increase in fat mass from baseline
in the heterozygotes compared to wild-type (Figure 3.1).
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3.4.2 Effect of arsenic on serum cytokines
To determine the effect of arsenic on systemic inflammation, we chose to
examine the serum cytokines. Both TNF-α and IL-1β were below the limit of detection,
and therefore excluded. There was no significant difference in IL-6 in circulation based
on treatment group or genotype for males or females (Figure 3.2), however there were
sextypic differences in the heterozygotes. In the males exposed to 10x arsenic, there is a
large increase in IL-6 in circulation, but in females as arsenic exposure increases in the
heterozygotes IL-6 in circulation decreases, demonstrating that males may have more
proinflammatory cytokines in circulation in response to arsenic exposure.

3.4.3. Effects of arsenic on spleen cytokines
To further examine the effects of arsenic on systemic inflammation, and because
cytokines are short-lived in circulation, we also evaluated cytokine levels in the spleen. In
the male heterozygotes, IFN-γ was decreased in the 1x arsenic treatment group, but this is
not present or amplified in the 10x treatment group (Figures 3.3 and 3.4). This differed
greatly from the response in the females, where in the wild-type mice IFN-γ and IL-1β
were significantly increased (Figure 3.5). In the female heterozygotes, IL-13 was
significantly decreased between 1x and 10x treatment groups but IL-10 and IL-4 were
significantly increased from 1x-10x treatment groups (Figure 3.6). This demonstrated that
in females, depending on genotype, arsenic can either induce a more proinflammatory
response in circulating cytokines or anti-inflammatory response.
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3.4.4 Effect of arsenic on local inflammation
We wanted to examine the effects of arsenic exposure on local inflammation, and
to do this we chose to evaluate changes in macrophage expression. With changes in body
composition, there are changes in macrophage populations. As fat mass increases, there is
a shift from balanced M1/M2 macrophage phenotypes to a pro-inflammatory M1
phenotype. In adipose tissue, this is typically correlated with an increase in macrophage
accumulation in tissue (Kathryn, Wellen, & Gokhan, 2003). In Figures 3.7 and 3.8, we
did not see a change in expression of either inducible nitric oxide synthase (iNOS) (M1),
arginase (M2), or CCL2 (macrophage recruitment) in either males or females after
arsenic exposure. However, there were overall differences in the heterozygous males
exposed to 10x arsenic; while not significant, arginase, iNOS, and CCL2 were reduced
compared to the 1x treatment group (Figure 3.7). There were also non-significant
sextypic differences, as CCL2 in 1x arsenic-exposed heterozygous males was increased
from control, where in 1x arsenic-exposed heterozygous females CCL2 was reduced.
We chose the same method of assessment in the spleen, however, unlike in the
adipose tissue, male heterozygotes in the 10x treatment group showed an increase in
expression in both iNOS and arginase (Figure 3.9). There were minimal changes in
expression in either gene in the wild-type males, indicating there were no changes in
macrophage population. Females had no significant change in either iNOS or arginase
based on exposure to arsenic (Figure 3.10). However, when examining differences
between the two genes, female wild-type mice had a decrease in arginase and an increase
in iNOS when exposed to arsenic.
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Finally, we wanted to evaluate changes in macrophage populations in the liver, as
this is the primary organ for detoxification. We saw no significant changes in male
(Figure 3.11) or female (Figure 3.12) liver expression of arginase or iNOS with arsenic
exposure. While not significant, there is a large increase in the expression of iNOS in the
male heterozygotes exposed to 10x arsenic. This differs from the female heterozygotes
exposed to 10x arsenic, where there is a decrease in iNOS expression.

3.5 Discussion
Overall, there were differences in inflammation caused by arsenic exposure in
both sexes, genotypes and treatment groups. Most studies focusing on the effects of
arsenic exposure are limited in scope to the effects on the development of type 2 diabetes.
Here, we present a case for low-dose arsenic exposure, similar to exposure levels in the
United States, wherein arsenic is not diabetogenic but induces changes in the immune
response. We also present novel male and female data, since the majority of studies
examining the effects of arsenic have been limited to only males.
In circulating cytokines, males and females exhibited very different responses
depending on genotype. Where male heterozygotes had a decrease in IFN-γ when
exposed to 1x arsenic, female wild-type mice had an increase in IFN-γ. In female
heterozygotes, when increasing arsenic exposure from 1x to 10x arsenic there is a drastic
change in cytokine profile with an increase in IL-4 and IL-10 and a decrease in IL-13,
which demonstrates changes in the anti-inflammatory environment. Overall, the
circulating inflammatory environments for each of these treatment groups is very
different. Where wild-type males were not affected, the change in male heterozygotes
indicates a decrease in inflammation. In the female wild-type mice, arsenic increased
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both IFN-γ and IL-1β, which are both pro-inflammatory cytokines. For female
heterozygotes, as arsenic concentration increased, there was an increase in antiinflammatory cytokines. This is opposite of what we would have expected based on the
change in fat mass in the females, as the heterozygotes had the greatest increase in fat
mass. Based on current literature, this increase in fat mass in this genotype should have
had more pro-inflammatory cytokines in circulation, suggesting that the changes
exhibited in systemic inflammation were arsenic driven, not obesity driven.
To examine inflammation at a local level, we chose to evaluate gene expression
changes in organs that are affected by arsenic exposure: adipose tissue, liver and spleen.
These three tissues accumulate arsenic, and are vulnerable to exposures (ATSDR, 2013).
We hypothesized that since arsenic is typically an inducer of inflammation, the
macrophage populations in these tissues would shift from a balanced M1/M2 population
toward a primarily M1 population. To test this hypothesis, we chose three genes,
arginase, iNOS and CCL2 to determine the effects of arsenic on macrophage populations.
The primary organ affected was the spleen of heterozygote males. In this group, as
arsenic exposure increased, the expression of iNOS and arginase increased. This could be
due to an increase in total macrophage population. Female spleens, despite the increased
pro-inflammatory cytokines in circulation, were not affected at the tissue level.
Here we have presented that, depending on sex and genotype, arsenic has very
different effects on the immune system. Both of these mouse models represent a nonsusceptible population for diabetes, and while there was a significant difference in fat
mass in females based on genotype, all of the changes observed are correlated with
arsenic exposure. These findings will inform future analysis of arsenic and the
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development of diabetes in a susceptible model. While we cannot link these low levels of
arsenic to diabetes in our models, we can say that low-dose arsenic exposures can have
significant impacts on the immune system that warrant further exploration.
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Table 3.1. Real-time PCR Primer list.
ID
Forward 5’-3’

Reverse 5’-3’

CCL2

CAGCAGGTGTCCCAAAGAAG

ACCTTAGGGCAGATGCAGTT

iNOS

GAAGTTCAGCAACAACCCCA

TTCAAGATAGGGAGCTGCGA

Arginase

CCCTGCCAATCATGTTCCTG

GAGAAAGGGGCTCCGACTAT

RPLP0

CCTGAAGTGCTCGACATCAC

GCGCTTGTACCCATTGATGA

Abbreviations: Chemokine ligand 2 – CCL2, Inducible nitric oxide synthase – iNOS,
Ribosomal protein lateral stalk subunit P0 – RPLP0
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Figure 3.1. Arsenic does not significantly alter change in fat mass. Change in fat mass from 4 weeks to 12 weeks old in male and
female mice. Female wild-type mice have a significantly lower change in fat mass than female heterozygotes without arsenic exposure.
Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using linear regression followed
by Tukey’s multiple comparison test and is indicated as * (p<0.05).
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.
Figure 3.2. Arsenic has no effect on serum IL-6 levels. Serum cytokine profile of male and female wild-type and heterozygous
mice. There were no significant differences present in IL-6 levels in circulation in either males or females. Cytokines were measured
by Bio-Plex. Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using linear
regression followed by Tukey’s multiple comparison test and is indicated as * (p<0.05).
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Figure 3.3. Arsenic reduces IFN-γ in spleen of male heterozygotes. Spleen cytokine analysis of male wild-type and heterozygotes
after 8 weeks of arsenic exposure. IFN-γ was significantly reduced in male heterozygotes. Cytokines were measured by elisa and the
results calculated as pg/g spleen tissue. Data are represented as the mean of each treatment group ± SEM. Statistical significance was
assessed using linear regression followed by Tukey’s multiple comparison test and is indicated as * (p<0.05).
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Figure 3.4. Increase in arsenic exposure does not affect IFN-γ in male heterozygotes. Spleen cytokine analysis of male
heterozygotes after 8 weeks of arsenic exposure. IFN-γ was reduced in male heterozygotes in the 1x arsenic treatment group, but this
was not exacerbated by increasing exposure levels. Cytokines were analyzed by elisa and the results calculated as pg/g spleen tissue.
Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using linear regression
followed by Tukey’s multiple comparison test and is indicated as * (p<0.05).
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Figure 3.5. Arsenic exposure increases IL-1β and IFN-γ in wild-type females. Spleen cytokine analysis of female wild-type and
heterozygotes after 8 weeks of arsenic exposure. Female wild-type mice had a significant increase in IFN-γ and IL-1β caused by
arsenic exposure. Cytokines were measured by elisa and the results calculated as pg/g spleen tissue. Data are represented as the mean
of each treatment group ± SEM. Statistical significance was assessed using linear regression followed by Tukey’s multiple comparison
test and is indicated as * (p<0.05).
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Figure 3.6. Increase in arsenic exposure affects female heterozygote spleen cytokines. Spleen cytokine analysis of female
heterozygotes after 8 weeks of arsenic exposure. Increase from 1x to 10x arsenic exposure increased IL-10 and IL-4 concentration, but
decreased IL-13 concentration. Cytokines were measured by elisa and the results calculated as pg/g spleen tissue. Data are represented
as a mean of each treatment group ± SEM. Statistical significance was assessed using linear regression followed by Tukey’s multiple
comparison test and is indicated as * (p<0.05).
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Figure 3.7. Arsenic exposure does not affect adipose tissue cytokine expression in males. In male adipose tissue, arginase, iNOS,
and CCL2 expression was determined by RT-PCR. Arsenic did not have an effect on the expression of any analyzed genes. All data
were normalized to RPLP0. Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed
using linear regression followed by Tukey’s multiple comparison test and is indicated as * (p<0.05).
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Figure 3.8. Arsenic exposure does not affect adipose tissue cytokine expression in females. In female adipose tissue, arginase,
iNOS, and CCL2 expression was determined by RT-PCR. Arsenic did not significantly alter any of the analyzed genes. All data were
normalized to RPLP0. Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using
linear regression followed by Tukey’s multiple comparison test and is indicated as * (p<0.05).
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Figure 3.9. Increase in arsenic exposure affects macrophage gene expression in male heterozygote spleens. Male heterozygotes
had an increase in arginase and iNOS expression in the spleen after 8 weeks of 10x arsenic exposure. Arginase and iNOS expression
was determined by RT-PCR. All data were normalized to RPLP0. Data are represented as the mean of each treatment group ± SEM.
Statistical significance was assessed using linear regression followed by Tukey’s multiple comparison test and is indicated as *
(p<0.05).
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Figure 3.10. Arsenic exposure does not affect spleen cytokine expression in females. In females no change was observed in the
spleen after 8 weeks of 10x arsenic exposure. Arginase and iNOS expression was determined by RT-PCR. All data were normalized to
RPLP0. Data are represented as a mean of each treatment group ± SEM. Statistical significance was assessed using linear regression
followed by Tukey’s multiple comparison test and is indicated as * (p<0.05).
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Figure 3.11. Arsenic exposure does not affect male macrophage gene expression in the liver. In males, there was no change in
gene expression in the liver after 8 weeks of 10x arsenic exposure. Arginase and iNOS expression was determined by RT-PCR. All
data were normalized to RPLP0. Data are represented as a mean of each treatment group ± SEM. Statistical significance was assessed
using linear regression followed by Tukey’s multiple comparison test and is indicated as * (p<0.05).
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Figure 3.12. Arsenic exposure does not affect female macrophage gene expression in the liver. In females, there was no change in
gene expression in the liver after 8 weeks of 10x arsenic exposure. Arginase and iNOS expression was determined by RT-PCR. All
data were normalized to RPLP0. Data are represented as the mean of each treatment group ± SEM. Statistical significance was
assessed using linear regression followed by Tukey’s multiple comparison test and is indicated as * (p<0.05).

Chapter 4 – Arsenic and Macrophages
4.1 Introduction
Arsenic is a ubiquitous element found in the earth’s crust that can be naturally
occur in organic and inorganic forms. Typical arsenic exposure is about 50 µg/day, with
about 3.5 µg/day from inorganic sources and the remainder from non-toxic organic
sources (ATSDR, 2013). The main exposures to inorganic arsenic occur from ingestion
of contaminated food and water. In the United States, the amount of arsenic in public
drinking water is very highly regulated, and was recently reduced from 50 µg/L to 10
µg/L by the EPA in 2001 based on its carcinogenicity (ATSDR, 2013). Besides cancer,
arsenic has been linked to a number of diseases, including cardiovascular disease, type 2
diabetes and immunological disorders (Mandal & Suzuki, 2002).
When considering arsenic and type 2 diabetes, inflammation must be addressed.
The inflammatory profile of a non-diabetic is very different from that of a diabetic
individual, and arsenic as an immunotoxic agent can exacerbate this situation. Arsenic,
has previously been found to modulate the overall immune profile in both lean and obese
individuals by affecting gene expression, cell population and ROS production
(Dangleben et al., 2013; Mandal & Suzuki, 2002; Tobergte & Curtis, 2013). However, in
obese individuals, the systemic and local inflammatory profile contains more proinflammatory components, such as M1 macrophages, whereas lean individuals will have
a balance of M1 to M2 macrophages (Mosser & Edwards, 2008). Arsenic has been shown
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to affect macrophages (Lemarie et al., 2006), therefore it could be suggested that arsenic
would have different effects on the immune system in lean and obese individuals.
In this study we proposed to examine the effects of sub-cytotoxic levels of arsenic
on Raw 264.7 macrophages in both normal and high glucose environments, to represent
non-diabetic and nondiabetic individuals, respectively. By varying glucose concentration,
we were able to model the effects of arsenic in both normal and high blood glucose
scenarios, similar to a normal and hyperglycemic individual and the stress that is put on
the macrophages in each scenario. We evaluated gene expression changes in these
macrophages by real-time PCR to determine whether they are more pro-inflammatory
after an immune challenge following exposure to arsenic. We chose to evaluate these
gene expression changes after either 3 or 24 hours of arsenic exposure to demonstrate
differences in acute and chronic exposure, as arsenic has a half-life in the blood of
approximately 3 hours (ATSDR, 2013) We hypothesized that arsenic exposure and
higher concentrations of glucose will increase inflammatory cytokine expression in
macrophages, especially over a period of chronic exposure.

4.2 Methods
4.2.1 Cell culture
Raw 264.7 macrophages (ATCC) were grown to confluence in high or low
glucose Dulbecco’s Modified Eagle Medium (DMEM, Hyclone) with 2% FBS (Hyclone)
and 1% penicillin/streptomycin (ThermoFisher) at 37°C and 5% CO2. Cells were
stimulated with lipopolysaccharide (Sigma-Aldrich) at 50ng/ml for 4 hours after exposure
to inorganic arsenic (AsCl3 - Alfa Aesar,) in a serial dilution ranging from 1x10-7µM to
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100µM for 3-24 hours to determine sub-cytotoxic concentrations to be used in future
experiments

4.2.2 Cell viability
Cell viability was determined using CellTiter 96 Aqueous One Solution Cell
Proliferation Assay (Promega) according to manufacturer’s instructions. Cells were
grown to confluence and then incubated with arsenic (0-100 µM) for 3 hours to
determine sub-cytotoxic doses to be used in subsequent experiments.

4.2.3 Gene expression
RNA was isolated from cells using Isolate II kit (Bioline) according to
manufacturer’s protocol with quantity and quality measured spectrophotometrically via
260/280 ratio. Real-Time PCR was then performed using SensiFast 1-Step Sybr Green kit
(Bioline) for PCR according to manufacturer’s protocol with 1ng RNA and 10 µM of
designed and validated primers. Custom primers (Table 4.1) were designed for each
target using Primer Blast Search (NCBI) and purchased from Integrated DNA
Technologies (IDT) for qPCR. Gene expression patterns for each gene were normalized
to the expression of the housekeeping gene RPLP0 and quantified using the ΔΔCT
method.

4.2.5 Statistics
All statistical analyses were carried out using GraphPad Prism 7 Software (San
Diego, CA). Results are expressed as the mean ± SEM, and all experiments were
performed in triplicate to test reproducibility of results. Multiple comparisons were made
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using one-way analysis of variance (ANOVA), followed by post hoc analysis using
Tukey’s method. A p-value of <0.05 was considered statistically significant.

4.3 Results
4.3.1 Cell viability
We wanted to establish sub-cytotoxic doses of arsenic to be used in the
RAW264.7 macrophage experiments. The MTT assay (Figure 4.1), which determines cell
viability colormetrically, demonstrated that any concentration greater than 0.1 µM had
significantly reduced survival, as absorbance in the assay dropped from 2.74 to less than
0.5.

4.3.2. Three-hour arsenic exposure in low glucose
Based on our hypothesis that sub-cytotoxic exposure to arsenic will modify
cytokine gene expression in macrophages, we examined the changes in gene expression
that occur at 3 hours of exposure in normal glucose concentrations. As arsenic
concentrations increase from low (0.001µM) to high (0.01µM), there were no changes in
cytokine expression in IL-10, TNF-α, STAT3 or TGF-β (Figure 4.2). These findings do
not support our initial hypothesis that higher levels of arsenic exposure are enough to
drive a pro-inflammatory response in macrophages.

4.3.3. Three-hour arsenic exposure in high glucose
In a diabetic state, as blood glucose increases we would expect the inflammatory
state of macrophages to change from neutral to pro-inflammatory. Therefore, by adding
in the inflammatory modulator of arsenic should cause a change in macrophage state,
most likely pushing them toward a pro-inflammatory state. Here, we demonstrated that as
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arsenic concentration increases, the expressions of IL-10 significantly decreased (Figure
4.3). These findings support our hypothesis of increasing arsenic exposure increases a
pro-inflammatory response as IL-10 is an anti-inflammatory cytokine that inhibits Th1
immune responses (Couper, Blount, & Riley, 2008).

4.3.4. Twenty-four-hour arsenic exposure in low glucose
We wanted to determine whether increasing the exposure time, similar to a more
chronic level of arsenic exposure, would affect expression of cytokines by macrophages
differently than short-term exposure. As expected, in low glucose, there was no
significant changes in gene expression induced by arsenic exposure (Figure 4.4),
demonstrated by no significant changes in gene expression in IL-10, TNF-α, STAT3 or
TGF-β. This does not support our hypothesis that increasing the duration of arsenic
exposure (acute vs chronic) would increase the expression of pro-inflammatory cytokines
in macrophages.

4.3.5. Twenty-four-hour arsenic exposure in high glucose
Finally, we wanted to determine the effects of chronic arsenic exposure on
macrophages cultured in a high glucose environment, modeling a diabetic individual
being exposed to the additional stressor of arsenic. After stimulation with LPS, we saw
no significant changes in gene expression induced by arsenic exposure in IL-10, TNF-α,
STAT3 or TGF-β (Figure 4.5), suggesting that chronic arsenic exposure does not induce
inflammatory changes in macrophages.

92

Discussion
We expected to see changes in cytokine expression in macrophages exposed to
arsenic as arsenic trioxide has been shown to increase TNF-α and IL-8 secretion and
expression significantly in macrophages isolated from human peripheral blood
mononuclear cells (PBMCs). (Lemarie et al., 2006). We found that the lower
concentrations of arsenic had the greatest impact on macrophage cytokine expression,
specifically IL-10, at 3 hours in high glucose. IL-10 is an anti-inflammatory cytokine, and
an increase in production would result in diminished M1 and Th1 (pro-inflammatory)
responses (Couper et al., 2008), resulting in a suppressed immune response. In high
glucose conditions, both low and high arsenic concentrations lead to a reduction in IL-10
expression, but this did not correlate with longer exposure, therefore supporting the
possibility that acute arsenic exposure has a greater effect on immunity than chronic
exposure Validation of increased protein secretion would solidify these results. Due to
the importance of IL-10 in arsenic mediated macrophage changes, we also examined one
of the downstream targets of IL-10, STAT3, as it is known transcription factor for antiinflammatory macrophages (Martinez & Gordon, 2014) While there was a slight decrease
in expression at the highest arsenic concentration in the 3 hour high glucose treatment
group, it was not significantly affected, suggesting while gene expression is increased,
IL-10 protein in suspension may not be increased. However, this result could further be
explained by examining protein concentration of IL-10, as well as additional upstream
regulators targeting STAT3 such as IL-6, which is something we could explore in further
studies (H. M. Wilson, 2014). Also affected in this treatment, although not significantly,
was TGF-β. This is another anti-inflammatory cytokine, and with the combined decrease
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in expression in TGF-β and IL-10, we would have expected to see an increase in TNF-α
regulation, as TNF- α expression is negatively regulated by these cytokines. However,
this was not the case in our model demonstrated by no change in TNF-α expression
regardless of arsenic concentration, glucose concentration or time of exposure.
To gain better insight into the effects of arsenic exposure on M1 vs M2
macrophages, we would have to first differentiate our cell culture toward one of these
phenotypes prior to exposure. By doing so, we would be able to determine whether
arsenic is in fact modulating the entire immune response (both pro and antiinflammatory) by having our cells already skewed toward a specific phenotype. It is
interesting that the shorter arsenic exposure in high glucose appeared to have a greater
effect on gene expression in macrophages. This could indicate that for human exposure to
arsenic, the important changes to the immune system are more visible after acute
exposure.
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Table 4.1. Real time PCR Primer list.
ID
Forward 5’-3’

Reverse 5’-3’

TGF-β

TTGCCCTCTACAACCAACACAA

GGCTTGCGACCCACGTAGTA

IL-10

TGGACTCCAGGACCTAGACA

AGTGTGGCCAGCCTTAGAAT

STAT3

TACCATTGACCTGCCGATGT

TCCGAGGTCAGATCCATGTC

TNF-α

AGCACAGAAAGCATGATCCG

CTACAGGCTTGTCACTCGAA

RPLP0

CCTGAAGTGCTCGACATCAC

GCGCTTGTACCCATTGATGA

Abbreviations – Transforming growth factor beta – TGF-β, Interleukin 10 – IL-10, Signal
transducer and activator of transcription 3 – STAT3, Tumor necrosis alpha – TNF-α,
Ribosomal protein lateral stalk subunit P0 – RPLP0
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Figure 4.1. Raw 264.7 macrophage cell viability after arsenic exposure. Raw 264.7 macrophage viability after 3 hours of inorganic
arsenic exposure at concentrations ranging from 0-100µM.
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Figure 4.2. Short term arsenic exposure has no effect on macrophage cytokine expression in low glucose environment. Raw
264.7 macrophage gene expression after 3 hours of exposure in low glucose DMEM. mRNA levels are expressed relative to RPLP0.
Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using ANOVA, followed by
Tukey’s multiple comparison test.
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Figure 4.3. Short term arsenic exposure suppresses macrophage IL-10 expression in high glucose environment. Raw 264.7
macrophage gene expression after 3 hours of exposure in high glucose DMEM. mRNA levels are expressed relative to RPLP0. Data
are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using ANOVA followed by Tukey’s
multiple comparison test, and is indicated as * (p<0.05).
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Figure 4.4. Long term arsenic exposure has no effect on macrophage cytokine expression in low glucose environment. Raw
264.7 macrophage gene expression after 24 hours of exposure in low glucose DMEM. mRNA levels are expressed relative to RPLP0.
Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using ANOVA followed by
Tukey’s multiple comparison test, and is indicated as * (p<0.05).
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Figure 4.5. Long term arsenic exposure has no effect on macrophage cytokine expression in high glucose. Raw 264.7
macrophage gene expression after 24 hours of exposure in high glucose DMEM. mRNA levels are expressed relative to RPLP0. Data
are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using ANOVA followed by Tukey’s
multiple comparison test.

Chapter 5 – Conclusions and Future Directions
5.1 Baseline differences in genotype
In our research, we used two different mouse models (C57BL/6 and db/+) that are
both representative of controls used in various diabetic experiments. Both are considered
to be lean mice that do not develop type 2 diabetes under normal circumstances, but the
C57BL/6 mouse will develop diabetes slowly when fed a high fat diet. In many studies
that use the db/db mouse strain that become obese and diabetic around 4 weeks old, the
db/+ mouse strain is the control. However, based on our study the C57BL/6 and db/+
mouse strains have several differences before the introduction of an environmental
contaminant.
The evaluation of body composition in our C57BL/6 vs db/+ mice show the db/+
mice gain weight at a faster rate than our wild-type in both males and females. This
includes a higher body fat percentage in the females at 12 weeks of age and wild-type
males had slightly higher lean mass compared to the db/+ genotype (Table 5.1). Either of
these conditions would result in a change in the expected inflammatory profile (Table 5.2
and Table 5.3). This was validated by male db/+ having slightly higher concentration of
IL-13 in the spleen, and db/+ females having higher levels of IL-10 in spleen, TNF-α and
IL-1β in serum. So at baseline, the male heterozygotes are already demonstrating a higher
level of anti-inflammatory cytokines in circulation and females are more proinflammatory. For the chosen cytokines analyzed by gene expression the wild-type and
db/+ mice demonstrated no differences, but IL-13 was not among the chosen cytokines
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The female db/+ mice exhibited a wide range of gene expression changes in
adipose tissue and spleen that would point toward increased macrophage activity and
inflammation. Female db/+ mice also had higher levels of triglycerides in all organs
examined except for the liver (Table 5.4). There were no notable differences in males or
females in glucose tolerance.
Overall, besides body composition these mouse strains had varying differences in
local and systemic inflammation and triglyceride levels. This makes them very different
controls in experiments, so depending on the experiment certain changes may be
magnified or lessened depending on the measured outcome.

5.2 Effects of low dose arsenic on diabetes development
The development of diabetes in humans is complex, with only 1/3 of individuals
that develop insulin resistance along with obesity will become diabetic (Donath &
Shoelson, 2011). A family history may indicate future susceptibility to the disease, but
this alone does not guarantee an individual will develop diabetes. It is a combination of
factors that causes disease to occur. Our mouse models represented two different strains
that are not susceptible to obesity or diabetes, which gives us information needed to infer
ways in which the general public could respond to arsenic exposure. We observed that
low-dose arsenic exposure alone is not enough to induce diabetes development, although
it may cause slight changes in body composition and organ triglycerides (Table 5.5 and
Table 5.6). It would be beneficial to continue this study in a diabetes-susceptible model to
determine whether arsenic could impact the development of disease or shift disease onset,
now that we have defined the baseline response.
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We found that low-dose arsenic exposure causes varying effects to the immune
system that differ based on genotype and sex (Table 5.7 and Table 5.8). It was previously
demonstrated in C57BL/6 male mice that exposure to arsenic at 100µg/L reduced
immune response to influenza infection (Kozul, Ely, Enelow, & Hamilton, 2009). This
differs from what we observed in our male C57BL/6 mice, which demonstrated 1-fold
increase in circulating IFN-γ, IL-13 and IL-6 (Table 5.7).
Depending on the tissue examined, expression of these cytokines varied greatly
(Table 5.8). We chose to further determine what the effect of arsenic exposure on
macrophages in vitro, as these immune cell types are particularly affected as obesity
increases. We report here that at acute exposure in high glucose, arsenic significantly
reduced IL-10, an important anti-inflammatory mediator. While we did not see an overall
suppression of the macrophage cytokine response due to arsenic exposure, we can say
that depending on the stress placed on the cells (i.e. higher glucose concentration), there
will be a different immune response. This is important in the context of human exposures,
as no two individuals will have the same baseline stress levels, supporting the idea that
the effect of arsenic on the body will vary greatly from person to person.
We originally hypothesized that arsenic exposure would decrease glucose
tolerance in a non-susceptible mouse model, leading to an increase in type 2 diabetes
susceptibility. Instead, we have demonstrated through these experiments that low-dose
exposure to arsenic in a non-susceptible individual is not enough to drive diabetes, but it
is enough to cause changes to the immune response.
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Table 5.1. Summary of genotypic differences in body composition.

Lean

Fat

Total

Fat %

Males
Females
Lines represent no change, or a fold change from control less than 1. One small arrows
represent a fold change between 1-2 and 2 small arrows represent a fold change greater
than 2.
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Table 5.2. Summary of genotypic differences in systemic cytokines.
Spleen
TNF-α

GMCSF

IFN-γ

IL-13

IL-10

Serum
IL-1β

IL-4

IL-6

TNF-α

IL-6

IL-1β

Males

Females

Lines represent no change, or a fold change from control less than 1. One small arrows represent a fold change between 1-2 and 2
small arrows represent a fold change greater than 2
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Table 5.3. Summary of genotypic differences in immune-related gene expression.
Adipose Tissue
Adiponectin

Leptin

TNFα

Liver

Arginase

iNOS

CCL2

Arginase

Spleen
iNOS

Arginase

iNOS

Males
Females
Lines represent no change, or a fold change from control less than 1. One small arrows
represent a fold change between 1-2 and 2 small arrows represent a fold change greater
than 2.
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Table 5.4. Summary of genotypic differences in organ triglycerides

Muscle

Kidney

Liver

Heart

Males
Females
Lines represent no change, or a fold change from control less than 1. One small arrows
represent a fold change between 1-2 and 2 small arrows represent a fold change greater than 2.
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Table 5.5. Summary of arsenic effects on body composition.
Lean

Fat

Total

Fat %

Male WT
Male Het
Female WT
Female Het
Lines represent no change, or a fold change from control less than 1. One small arrows
represent a fold change between 1-2 and 2 small arrows represent a fold change greater
than 2. Light blue represents 1x arsenic exposure and dark blue represents 10x.
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Table 5.6. Summary of arsenic effects on organ triglycerides.
Muscle

Kidney

Liver

Heart

Male WT

Male Het

Female WT

Female Het
Lines represent no change, or a fold change from control less than 1. One small arrows
represent a fold change between 1-2 and 2 small arrows represent a fold change greater
than 2. Light blue represents 1x arsenic exposure and dark blue represents 10x.
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Table 5.7. Summary of arsenic effects on cytokines.
Spleen
TNF-α

GMCSF

IFN-γ

IL-13

IL-10

Serum
IL-1β

IL-4

IL-6

TNF-α

IL-6

IL-1β

Male WT
Male Het

Female
WT
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Female
Het

Lines represent no change, or a fold change from control less than 1. One small arrows represent a fold change between 1-2 and 2
small arrows represent a fold change greater than 2. Light blue represents 1x arsenic exposure and dark blue represents 10x.

Table 5.8. Summary of arsenic effects on immune-related gene expression.
Adipose Tissue
Adiponectin
Leptin
TNF-α
Arginase
iNOS
CCL2
Male
WT

Liver
Arginase
iNOS

Spleen
Arginase
iNOS

Male
Het

Female
WT
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Female
Het

Lines represent no change, or a fold change from control less than 1. One small arrows represent a fold change between 1-2 and 2
small arrows represent a fold change greater than 2. Light blue represents 1x arsenic exposure and dark blue represents 10x.
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